THE ASSOCIATION BETWEEN THE IL-1 PATHWAY by Wun, Isaac C.
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
5-2014
THE ASSOCIATION BETWEEN THE IL-1
PATHWAY
Isaac C. Wun
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Bioinformatics Commons, Biostatistics Commons, Cancer Biology Commons,
Computational Biology Commons, Genetics Commons, Medicine and Health Sciences Commons,
and the Survival Analysis Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Wun, Isaac C., "THE ASSOCIATION BETWEEN THE IL-1 PATHWAY" (2014). UT GSBS Dissertations and Theses (Open Access).
Paper 428.
  
 
 
 
THE ASSOCIATION BETWEEN THE IL-1 PATHWAY 
AND MELANOMA OUTCOMES 
 
by 
Isaac Wun, B.A., M.A. 
 
APPROVED: 
 
 
___________________________________________ 
Supervisory Professor: Christopher I. Amos, Ph.D. 
 
 
 
______________________________ 
Marsha Frazier (On-site advisor), Ph.D. 
 
 
 
______________________________ 
Jeffrey E. Lee, M.D. 
 
 
 
______________________________ 
Elizabeth Grimm, Ph.D. 
 
 
 
______________________________ 
Jeffrey Morris, Ph.D. 
 
 
 
 
 
Dean, The University of Texas 
Graduate School of Biomedical Sciences at Houston 
 
 
  
 
THE ASSOCIATION BETWEEN THE IL-1 PATHWAY 
AND MELANOMA OUTCOMES 
 
 
 
 
A  
DISSERTATION 
Presented to the Faculty of  
The University of Texas  
Health Science Center at Houston  
and 
The University of Texas 
MD Anderson Cancer Center 
Graduate School of Biomedical Sciences  
in Partial Fulfillment 
of the Requirements 
for the Degree of 
DOCTOR OF PHILOSOPHY 
 
 
by  
Isaac Wun, B.A, M.A. 
Houston, Texas 
May, 2014 
 
 
 
 
 
 
  
  
iii 
 
 
ACKNOWLEDGEMENTS 
 
      First and foremost, I wish to convey my utmost gratitude to my advisor, Dr. Christopher 
I. Amos, for all his advice, support, and time throughout my research process. I am glad for 
his guidance in helping me hone my knowledge and research skills. I also wish to convey my 
dearest thanks to my on-site advisor, Dr. Marsha Frazier, for all her counsel and patronage of 
me throughout this time. I owe the other members of my supervisory committee, Dr. Jeff 
Lee, Dr. Elizabeth Grimm, and Dr. Jeffrey Morris, my thanks as well, for their invaluable 
insights and suggestions for my project. I would also convey my thanks to my candidacy 
committee members: Dr. Marsha Frazier, Dr. Karen Basen-Engquist, Dr. Chongjuan Wei, 
Dr. Anthony Wright, and Dr. Subrata Sen, for taking the time to help me with my candidacy 
exam. I owe much to Ms. Wei Chen in the Genetics department. I would never have been 
able to obtain the necessary data for my project and properly coded for my analysis in such a 
smooth manner without her assistance. I would express my deep thanks to her. I would thank 
Dr. Florence Demenais, Pierre-Emmanuel Sugier, and their group in Paris for their validation 
analysis. I would also like to thank Dr. Victoria Knutson, Ms. Lourdes Perez, and the other 
GSBS staff members for all their support these past several years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iv 
 
 
THE ASSOCIATION BETWEEN THE IL-1 PATHWAY 
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 Cutaneous malignant melanoma (CMM) is a potentially lethal malignancy that 
warrants attention and further research, as it is known to that there is an increasing rate of 
incidence in the United States, and it is also known that exposure to UV light is its most 
crucial risk factor, and family history of melanoma is also an important risk factor. 
Melanoma is an aggressive and lethal cancer in humans. There are an estimated new 132,000 
melanoma cases annually worldwide, and the trend has doubled in the past 20 years. 
However, attempts to treat melanoma have encountered considerable resistance and remained 
ineffective. The 5-year survival rate for metastatic melanoma remains less than 5%. CMM 
patients may develop an immune response to their tumors, but innate anti-tumor immune 
responses are insufficient for controlling the development of the tumor. Melanoma is a very 
immunogenic tumor, sometimes exhibiting spontaneous remissions, making it one of the 
foremost targets for immunotherapy. Unfortunately, despite the attempts at making tumor-
infiltrating lymphocyte treatments, the clinical response has been borderline. The 
immunosuppressive microenvironment of tumor cells becomes significant and intertwines 
with the resistance of tumor treatment. Furthermore, IL-1 can hinder the immune response to 
melanoma. The pathway of MAPK activation leads to the production interleukin(IL)-1α/β. 
IL-1 conducts immunomodulatory activity through tumor-associated fibroblasts and locks in 
the turnkey position of the immunosuppression pathway to resist the cytotoxic T lymphocyte 
function. Hence, IL-1 is a key target of interest in treating melanoma, along with the entire 
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pathway flowing from it. Polymorphisms in genes regulating the immune response could 
result in increased susceptibility to and/or poorer prognosis in certain individuals. For this 
study, one of the objectives was to examine if single nucleotide polymorphisms (SNPs) of 
certain pro- and anti-inflammatory cytokines and growth factors, namely IL-1, IL-6, IL-8, 
IFN-γ, and TNF-α are associated with melanoma outcome of death, recurrence, or composite, 
and thus susceptibility. Those genes are the upstream and downstream targets for the greater 
IL-1 pathway. The greater IL-1 pathway has multiple genes in between those upstream and 
downstream targets. Those genes are IL-1RI, IL-1RAcP, IL-1RA, MYD88, TOLLIP, IRAKs, 
MEKK1, MEK3, MEK6, JNK, P38, c-JUN, ECSIT, TRAF6, TAB1, TAK1, RKIP, NIK, 
IKKα, IKKβ, IκBα, and NF-κB.  
 The individual SNP analysis proved to be interesting though inconclusive. There were 
some borderline significant results, such as associations of the SNPs rs16944, rs1143627, 
rs1071676, and rs3136558 with the endpoint of death. The French validation verified a 
significant association of rs3136558 with death but none of the others. 
 The next objective was to perform a full pathway analysis, incorporating all available 
SNPs for each gene in the overall IL-1 pathway to determine if any components were 
significant and if so, to attempt further verification at the protein level if the data were 
available. By using the SKAT program for pathway analysis, several genes in the IL-1 
pathway were found to be significant. They were IL-1, c-JUN, and ECSIT, with borderline 
significance for TAK1.  
 With the observation of associations of these four genes with melanoma outcomes at 
the DNA level, the next step was to determine if they were also significantly associated with 
melanoma outcomes at the expression level. The data for the DNA level studies did not 
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include protein expression studies, so we used data provided by The Cancer Genome Atlas 
(TCGA). TAK1 data was not available, but RNA expression data were gathered for IL-1, c-
JUN, and ECSIT. At the protein level, only c-JUN data was available. At the RNA level, IL1 
showed that survival was proportional to IL-1 level, ECSIT showed lower survival for higher 
level, while c-JUN showed higher survival for higher levels. At the protein level, c-JUN was 
significant at the protein level, both adjusted and unadjusted via logistic regression. It seems 
that for developing further therapy against melanoma, c-JUN may be be a crucial target in the 
IL-1 pathway. IL-1 and ECSIT could also play important roles related to melanoma 
outcomes but require future studies where protein expression data is available to confirm the 
DNA- and RNA-based results. 
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Chapter 1 
Introduction 
1.1 Melanoma Lethality and Association with IL1 Pathway 
Melanoma is an aggressive and lethal cancer in humans. There are an estimated new 
132,000 melanoma cases annually worldwide, and the incidence has doubled in the past 20 
years (Gray-Schopfer et al., 2007). However, attempts to treat melanoma have remained 
largely ineffective. (Ivanov et al., 2003; Hersey et al., 2006; Gray-Schopfer et al., 2007; 
Segura et al. 2013). There are new concepts directed at enhancing the curability of melanoma 
(Gray-Schopfer et al., 2007; Finger et al. 2013; Segura et al. 2013), such as targeted therapy 
to control immunosuppression that typically develops in metastatic melanoma, inhibition of 
connective tissue growth factors, epigenetic approaches against core transcriptional activities. 
This study intends to use a bioinformatics approach to identify the critical elements for 
enhancing therapeutic effectiveness.  
Melanoma, as one of the most immunogenic tumors for which spontaneous immune 
responses and remissions can rarely occur, is one of the foremost targets for immunotherapy 
(Zito, 2012). Such attempts can stimulate tumor antigen-specific T-cells, but they are only 
effective for a few percent of individuals with metastatic melanoma (Alexandrescu, 2010).  
 The IL-1 pathway plays a key role in controlling immune response and particularly 
upregulation of IL-1 is associated with immunosuppression. The immunosuppression 
microenvironment of tumor cells becomes significant and intertwines with the resistance of 
tumor treatment. Khalili et al. (2013) explains that the pathway of MAPK activation leads to 
the production interleukin(IL)-1α/β. IL-1 conducts immunomodulatory activity through 
tumor-associated fibroblasts and holds the turnkey position of the immunosuppression 
pathway to resist the cytotoxic T lymphocyte function. Qin et al. (2011) showed that 
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blocking the IL-1 receptor with antibodies or siRNAs halted growth in IL-1-positive 
melanoma cells. This disruption of the IL-1 pathway also boosted autophagy in the IL-1-
positive melanoma cells. Hence, without such disruption, IL-1 dampens the immune 
response. These results suggest that IL-1 might play an important role in the etiology and 
treatment of melanoma, and thus IL-1 becomes the main variable in this bioinformatical 
study, along with the entire pathway flowing down from it. 
Figure 1 presents the greater IL-1 pathway. 
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Figure 1. This figure displays the full IL-1 pathway from the IL-1 initiators to the 
final downstream targets of IL-6, IL-8, IFN- γ, and TNF-α 
 
Khalili et al. (2013) shows that melanoma can by exacerbated by IL-1 and other 
cytokines, critical components of the immune system.  (Botella-Estrada, 2005) offers insights 
into the details of how these cytokines interrelate. Cytokines are small soluble glycoproteins 
generated by multiple types of cells in all human organs. Their primary purpose is to fulfill 
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communication among cells by binding to particular receptors. Cytokines regulate cell 
differentiation and growth in the immune system. Among T-helper cell (Th) subsets, Th1 and 
Th2 subsets originate from naïve T (Th0) cells. Th0 cells are T cells that have differentiated 
in bone marrow and undergone the thymal selection process. Each subtype is characterized 
by its own particular cytokine pattern. Several cytokines emerge from each type, but 
interferon-gamma (IFN-γ) is the most characteristic cytokine for Th1. Khalili et al. (2013) 
explains that Th1 and Th2 embody different sorts of immune responses. Th1 cells stimulate a 
delayed-type of hypersensitivity response. Th2 cells, on the other hand, incite humoral 
immunity. In order to maintain a well-regulated physiological state, there must be a balance 
between the two arms. That balance is maintained by IFN-γ which inhibits Th2 cells, while 
interleukin(IL)-4 and interleukin(IL)-10 inhibit Th1 cells. Dendritic cells also maintain a vital 
function in the formation of an effective immune response, since they are the most powerful 
antigen-presenting cells.  
 (Boyano, 2000) observed that cytokines are not only secreted by normal cells. Tumor 
cells also secrete cytokines, and one can expect the tumor versions to be deranged. Martinez-
Escribano, 2002 observes that various cytokines can exhibit opposite effects upon the growth 
of tumor cells, with examples being IL-10, interleukin-6 (IL-6), and IFN-γ. Martinez-
Escribano, 2002 goes on to explain that the outcome for melanoma can be difficult to predict, 
particularly when taking into account that the tumor cells interact in complicated ways with 
the immune system. IL-6 and IFN- γ can both either hinder proliferation of melanoma cell or 
accelerate the growth rate, depending on the melanoma stage. It is logical that analyzing IL-6 
and IFN-γ gene polymorphisms could help researchers to better understand the function of 
those cytokines in the immune response against melanoma cells. The results for the study 
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indicated that IL-6 might display opposite effects on melanoma cells, being an inhibitor for 
early stage melanomas and as a mitogen at more advanced stages of the cancer. It seems that 
IL-6 serums levels are higher and correlated with major tumor burdens along with lower 
survival rates. Martinez-Escribano, 2002 could not demonstrate a correlation between IFN- γ 
medium and/or high expression genotypes and a worse prognosis.  
All the previously mentioned cytokines are affected by IL-1 as the initiator, since they 
are all downstream targets in the IL-1 pathway. Thus, genetic variation in immune-regulating 
components such as cytokines, specifically of the IL-1 pathway, may lead to differences 
among individuals in immunosuppression response and susceptibility to melanoma. 
Therefore, this study is warranted in order to better identify which components of the IL-1 
pathway are crucial target for improving treatment of melanoma. Due to the potential 
opposite functions of IL-1, genetic variation in immune-regulating components, and 
microenvironment variation, the study of melanoma tumorigenic mechanisms is a very 
complex matter. It may be due to these complicated mechanisms that the treatment of 
melanoma is ineffective. To further elucidate this complex mechanism, this study intends to 
examine the relationship between gene activity of upstream and downstream targets for IL-1 
pathway, (i.e. IL-1, IL-6, interleukin(IL)-8, IFN-γ, and tumor necrosis factor-alpha (TNF-α)), 
correlation with the progression of melanoma using the bioinformatical approach. 
To further describe the downstream targets of the IL-1 pathway and their association 
with melanoma outcomes, various cytokines can exhibit opposite effects upon the growth of 
tumor cells, with examples being interleukin-10 (IL-10), interleukin-6 (IL-6) and interferon-
gamma (IFN-γ). Martinez-Escribano, 2002 notes that the outcome for melanoma can be 
difficult to predict, particularly when taking into account that the tumor cells interact in 
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complicated ways with the immune system. IL-6 and IFN-γ can both either hinder 
proliferation of melanoma cell or accelerate the growth rate, depending on the melanoma 
stage. They may encourage proliferation for advanced melanoma while inhibiting 
progression at the early stages. It is logical that analyzing IL-6 and IFN-γ gene 
polymorphisms could help researchers to better understand the function of those cytokines in 
the immune response against melanoma cells. The results for the Martinez-Escribano study 
indicated that IL-6 might display opposite effects on melanoma cells, being an inhibitor for 
early stage melanomas and as a mitogen at more advanced stages of the cancer. IL-6 serums 
levels are higher and correlated with major tumor burdens along with lower survival rates. 
The study could not demonstrate a correlation between medium and/or high expression 
genotypes for IFN-γ and a worse prognosis. (Martinez-Escribano, 2002) Another downstream 
target of the IL-1 pathway is IL-8. IL-8 could be associated with the potential for metastasis. 
It was noted by Singh (1995) that there were no detectable levels of mRNA transcripts in the 
majority of melanoma cases, only in the highly metastatic one. IL-1 upregulates IL-8 and thus 
induces its production.  
Earlier studies did find elevated IL-6 levels in melanoma patients. The paper noted 
that those studies had subjects with advanced-stage melanoma. As to why the levels of 
cytokines had been changed, some possibilities were cytokine production by the metastases, 
cytokine production by lymphocytes in response to the tumor, and perhaps there was a 
genetic factor regarding polymorphisms. (Porter, 2001)   
TNF-α is a cytokine that is produced in several types of cells, though mostly in 
mononuclear phagocytes. Cytotoxicity and anti-tumor activity stand amongst its various 
functions. As such, it bears a critical role in immune responses, along with proliferation and 
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inflammation. However, if the level  reaches excess, there can be toxic systemic effects. 
(Ocvirk, 2000) 
 
1.2 Therapeutic Difficulties and Potential 
Despite the immense potential of immunotherapies for cancer, a persistent barrier has 
been the obstruction posed by complexities in the tumor microenvironment, with agents and 
cells secreting immunosuppressive effects. The mechanisms for initiating and maintaining 
immunosuppression in neoplastic lesions to permit tumor growth is a matter that remains to 
be explained. The article by Khalili et al. (2013) noted that immunosuppression can be 
initiated by the upregulation of v-raf murine sarcoma viral oncogene homolog B (BRAF), 
mutated to the active form, BRAFV600E, in more than half of melanoma patients. They noted 
BRAFV600E-induced transactivation of genes coding for both interleukin-1α (IL-1α) and 
interleukin-1β (IL-1β) in melanocytes and wild-type BRAF-expressing melanoma cells. 
However, the results did not display a clear correlation between the V600E mutation and the 
production of those cytokines.  
As noted before, IL-1 is a pleiotropic cytokine that is expressed by many tumor types. 
With various models, IL-1 shows either protumor or antitumor functions. Khalili et al. (2013) 
discusses that the results seem to indicate that the oncogene driven activation of the MAPK 
pathway can induce tumor cells to secrete factors that modulate the immune response. MAPK 
include p38 and JNK, which stimulate c-JUN. Among those factors, IL-1 by itself can induce 
a sequence for the immunosuppressive activity of tumor-associated fibroblasts (TAFs). It is 
indicated that oncogene activation has a significant effect on the tumor microenvironment, 
and multiple factors are involved. Furthermore, the effect seems shifted more towards the 
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side of immunosuppression. Khalili et al. (2013) observes that Anakinra and other such 
clinical drugs that block IL-1 are already available, and there are already clinical trials in 
cancer patients currently being conducted to test the efficacy of this drug for standalone 
intervention. There are no results yet from those trials. It was also noted that IL-1 can directly 
encourage the growth and survival of melanoma cells, one of its pro-tumor functions. 
Therefore, there is both sound logic and strong incentive to focus on IL-1 in the melanoma 
tumor microenvironment as a clinical target.  
 Melanoma being so closely tied to the immune system means that there is 
considerable potential for immunotherapy, which is all the more reason to study the cytokine 
polymorphisms in order to better refine such potential treatments regimens. This possibility 
has been considerably explored for human malignant melanoma (Zito, 2012). One major 
reason for that is because melanoma overall seems rather resistant to chemotherapy and 
radiotherapy (Pak, 2001).  
To further the idea, while one of this study's hopes is to clarify potential targets for 
chemotherapy, immunotherapy is a viable alternative method for treating late-stage 
melanoma. There is still much to be learned, such as why melanomas become resistant 
toward an immune system that has been sensitized towards it. There are some potential 
mechanisms regarding tumor resiliency even when facing tumor-reactive T cells. 
Specifically, the absence of tumor-associated antigens (TAA) or HLA molecule expression 
might allow some melanomas to develop a stealth field of sorts that masks tumor cells from 
immune system recognition. Garrido F, Algarra I. (2001) noted that 63% of melanoma 
display loss of HLA class I expression. Mocellin, 2001 speculates that there is a possibility 
that other mechanisms in the tumor micro-environment, such as secretion of immune-
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suppressive cytokines from the tumor, might affect immune responsiveness. (Mocellin, 
2001). As an example, Estrozie et al. (2014) reported the upregulation of BRAF in vertical 
growth of cutaneous melanoma in young patients. For older patients, BRAF mutation may 
not be the dominant factor for the tumor genesis of melanoma. Khalili et al. (2013) suggested 
that the BRAF (mutated active form BRAFV600E) activation of the mitogen-activated protein 
kinase (MAPK) pathway enhances the production of a number of immunosuppression factors 
by tumor cells.  
 Thus far, there has been no statistically significant difference between subjects 
receiving tumor vaccines as compared with those receiving a placebo. Leong, 2002 discusses 
that Th1 cells secrete IL-2, and IFN-γ and play a major role in generating cell-mediated 
immunity such as delayed hypersensitivity reaction and the generation of cytotoxic T cells, 
which are important for destroying cancer and virally infected cells. Despite the fact that Th1 
and Th2 cells are defined by specific cytokines configurations, their interactions with one 
another are complex. Furthermore, it must be stressed that relationship between specific 
antigens and the associated cytokines produced is not completely understood, and when it 
comes to cancer immunology, that is doubly so.  
 The hypothesis for this study is that the SNPs and genes of the IL-1 pathway should 
show an association, protective or detrimental, with melanoma outcome. Identifying genes 
that are involved in melanoma formation and progression may suggest chemoprevention or 
immunotherapy targets or allow for identification of groups with high risks.  
1.3 Overview of Assessment Levels and Results 
Specifically, in order to better understand the genetic factors that might alter the 
disease risk level, the purpose of the study is to assess the association between potential gene 
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sequences with the progression of melanoma based on the following three major endpoints: 
death, recurrence, and the composite of death and/or recurrence.  
This relationship was assessed at the following levels: 
a) Individual SNP level for a list of candidate genes with external validation 
b) Gene level analysis, including all available SNPs for all pathway genes 
c) Those genes found to be significant from the full pathway analysis were also 
verified at the  
- RNA expression level, and 
- Protein expression level 
Figure 1 presents a flowchart summarizing these three levels of analysis and the 
corresponding results. It can be referred to the methods and results sections. Identifying 
genes that are involved in melanoma progression may suggest chemoprevention or 
immunotherapy targets or allow for identification of groups with high risks.   
 
  
 
 
 
 
 
Figure 2. Figure 2 is an analysis flowchart that summarizes the results. 
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Chapter 2 
Materials and Methods 
 The detailed methodologies are described below for each level of the analysis listed 
above in the introduction section. Figure 1 presents a flowchart of the process.  
 
2.1 Individual SNPs Analysis with External Validation 
The relationships between individual SNPs on the studied genes with melanoma 
outcomes of death, recurrence, and composite outcome of death and/or recurrence were 
assessed for the following upstream and downstream targets for the IL-1 pathway, i.e. IL-1, 
IL-6, IL-8, IFN-γ, and TNF-α. There were a total of 20 individual SNPs that were assessed. 
The specific SNPs analyzed for IL-1 were rs1800587, rs17561, rs2071374, rs16944, 
rs1143627, rs1071676, rs1143634, and rs3136558. For IL-6, the SNPs were rs1800795 and 
rs1800797. For IL-8, the analyzed SNPs were rs4073, rs2227307, and rs2227306. For IFN-γ, 
the SNPs were rs2430561, rs1861494, rs2069705. For TNF-α, the SNPs were rs361525, 
rs1799964, rs1800630, and rs1800629. The gene activity was assessed by 0, 1, and 2 copies 
of the ancestral allele types. The source data for this analysis includes cases (n=1804) that 
were drawn from a case-control study of malignant melanoma (n=931) and a case-series 
(n=873) all collected at the University of Texas MD Anderson Cancer Center (MDACC). All 
cases were required to have cutaneous malignant melanoma. Samples were genotyped by the 
Center for Inherited Disease Research using the Omni 1M Quad V1-0_B SNP chip.  Quality 
control procedures were implemented at MDACC and at the University of Washington 
through GENEVA. During quality control processing, individuals were removed who had 
estimated identity by descent > 0.15 (2 or more alleles would be identical by descent if they 
originate from the same ancestral allele without recombination), or who failed standard QC 
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using PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) or Eigenstrat. DNA segments are 
identical by state (IBS) for 2 or more individuals if the nucleotide sequences are identical in 
that segment. An IBS segment is in turn identical by descent (IBD) for 2 or more individuals 
if it is inherited from a common ancestor without recombination. After filters for Hardy-
Weinberg equilibrium (p>0.0001), minor allele frequency > 0.05, and missing genotypes 
<0.05, there were 818,237 SNPs available for analysis. The lambda value without principal 
component correction after excluding SNPs with minor allele frequency < 0.05 was 1.01, 
which decreased to 1.009 after correcting for the first two principal components. The lambda 
value represents the genomic control inflation factor. It is the ratio of the median of the 
observed distribution of the test statistic to the expected median, embodying the extent of 
bulk inflation and false positive rate. A lambda value above one would indicate population or 
genotyping errors.  
Demographic and clinical data were also captured in the MD Anderson database, 
including ethnicity, age of diagnosis, gender, Clark level, tumor stage, and Breslow index 
(more information about the database can be found in the e-book 60 Years of Survival 
Outcomes at The University of Texas MD Anderson Cancer, chapter 2 by Sarah H. Taylor). 
These variables were taken into account as covariates in the analysis. Ethnicity is not an 
issue, as all the subjects are white. Age of diagnosis and Breslow index were treated as 
continuous variables, while tumor stage and Clark level were categorized into the two 
following groups as binary variables respectively: tumor stage III & IV vs. I & I/II; Clark 
level 4 & 5 vs.  level 1, 2, & 3.  For each of the three melanoma endpoints, time to event 
from first diagnosis date to the first occurrence of event date was calculated in months. The 
analysis data set was prepared in comma-separated values (CSV) format by combining 
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clinical data with genotype data for each test subject. The relationships between genotype 
and time to each of the three melanoma outcomes were assessed by Cox proportional hazard 
(PH) regression analysis (both unadjusted and adjusted). A final multivariate Cox PH model 
was established by stepwise regression analysis. The hazard ratios (HR) and 95% confidence 
intervals (CI) for per ancestral allele copy decrease were calculated to assess whether there 
was a protective or harmful association with the event rate for each of the three melanoma 
endpoints. These analyses were carried out by Statistical Analysis Software (SAS) Version 
9.2.  
 Validation was also carried out for the individual SNP analysis in France lead by Dr. 
Florence Demenais, Directrice d'Unité : DR1 Inserm, of l'Université Paris Diderot - Paris 7, 
l'Institut Universitaire d'Hematologie. They analyzed the same 20 SNPs of the 5 genes 
focused upon for this study, or the closest available SNPs if the specified ones were not 
available. Using their own data collected from the French MELARISK cohort including 1179 
melanoma cases, they also adjusted for the same set of covariates of ethnicity, age of 
diagnosis, gender, Clark level, tumor stage, and Breslow index. Ethnicity was not an issue, as 
all were of western European descent. Dr. Demenais' group also used a multivariate Cox PH 
model established by stepwise regression analysis. Recurrence data was not available for 
them, so they used the endpoint of death only. 
 
2.2 Full Gene-Based Pathway Analysis 
Given the limited power presented by single marker association studies, especially 
rare variants, a pathway analysis including available SNPs for all the genes in the IL-1 
pathway was necessary.  Besides the sole upstream target, IL-1, and the downstream target of 
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IL-6, IL-8, IFN-γ, and TNF-α, this pathway analysis also include the following genes in the 
middle of IL-1 pathway: IL-1RI, IL-1RAcP, IL-1RA, MYD88, TOLLIP, IRAKs, MEKK1, 
MEK3, MEK6, JNK, p38, c-JUN, ECSIT, TRAF6, TAB1, TAK1, RKIP, NIK, IKKα, IKKβ, 
IκBα, and NF-κB. 
 For the pathway analysis, the sequence kernel association test (SKAT) package for R 
was utilized. The variables of age of diagnosis, gender, Clark level, stage, and Breslow index 
were adjusted for as covariates. As per Wu et al. (2011) [11], SKAT is a supervised test 
meant for examining the joint effects of multiple variants upon a phenotype in a region. 
Regions are defined by using genes (in candidate gene or whole exome studies) or moving 
windows across the genome (in whole genome studies). For each such region, SKAT will 
calculate a p-value for association while adjusting for covariates. Adjustments for multiple 
comparisons are necessary for analyzing multiple regions, e.g. using the Bonferroni 
correction or false discovery rate (FDR) control. Genes were defined with specific windows 
per the GRCh37 build. They would be as follows: 
 
IL-1α: 
Chromosome 2; 113531492 to 113542971, complement 
IL-1β:  
Chromosome 2; 113587337 to 113594356, complement 
IL-6:  
Chromosome 7; 22766766 to 22771621 
IL-8: 
Chromosome 4; 74606223 to 74609433 
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IFN-γ: 
Chromosome 12; 68548550 to 68553521, complement 
TNF-α:  
Chromosome 6; 31543344 to 31546113  
As for notation, as per the paper by Wu et al., one would assume n subjects are 
sequenced in a region with p variant sites observed. Covariates might include such factors as age 
and gender. For the i-th subject, yi denotes the phenotype variable, Xi=(Xi1, Xi2, .., Xim) the 
covariates, and Gi=(Gi1, Gi2, …, Gip) the genotypes for the p variants within the region. One 
would make the assumption of an additive genetic model and let Gij,=0, 1, or 2 represent the 
number of copies of the minor allele. Regarding how SKAT operates, using the example in 
the paper, one would test for the relationship between genetic variants and phenotype with 
multiple linear and logistic regression. One would use the following linear model: 
yi = α0 + α'Xi + β'Gi + εi 
for phenotypes that are continuous traits. The following logistic model would be used for 
dichotomous traits such as outcome of case or control (y = 0/1 for case/control): 
logit P(yi = 1) = α0 + α'Xi + β'Gi 
α0 would be the intercept term, α=[α1,..., αm]' is the vector of regression coefficients for the m 
covariates, β=[β1,…,βp]' is the vector of regression coefficients for the p observed gene 
variants in the region, and for continuous phenotypes εi stands for the error term with mean 
zero and variance σ2. With both the linear and logistic models, analyzing if the gene variants 
influence the phenotype, adjusting for covariates, corresponds to testing the null hypothesis 
H0: β=0, i.e. β1=β2=…=βp=0. The typical p-DF likelihood ratio test would have little power, 
especially in regards to rare variants. Therefore, to increase the power, SKAT tests H0 by 
assuming each βj follows an arbitrary distribution with mean zero and variance wjτ, with τ 
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being a variance component and wj a pre-specified weight for variant j. With the null 
hypothesis of H0: β=0, this test is equivalent to testing H0: τ=0. A variance component score test 
can be constructed in the following mixed model, which is known to be a locally most powerful. 
One crucial advantage of this score test is that it only requires fitting the null model 
yi=α0+α1'Xi+εi for continuous traits and logit P(yi=1)= α0+α1'Xi for dichotomous traits.  
The variance component score statistic is: 
Q = (y - û)' K(y - û) 
where, K=GWG', û is the predicted mean of y under H0, i.e. û = â0 + Xâ, for continuous traits 
and û  = logit-1(â0 + Xâ) for dichotomous ones. â0and â are estimated under the null by 
regressing y on only the covariates X. G is a n×p matrix with the (i,j)-th element being the 
genotype of variant j of subject i, and W=diag(w1,…, wp) contains the weights of the p variants. 
K is an n×n matrix with (i,i')-th element equal to K(Gi, Gi') being the summation of j = 1 to p for 
wjGijGi'j. K(,) is the linear kernel function and K(Gi, Gi') measures the similarity between 
subjects i and i' in the region using the p markers. This form of K(, ), as just demonstrated by 
K(Gi, Gi'), is called the weighted linear kernel function. Each weight wj is specified 
beforehand by utilizing the genotypes, covariates, and external biological information, i.e. 
without using the outcome. It reflects the relative contribution of the j-th variant to the score 
statistic: if wj is close to zero, the j-th variant makes only a small contribution to Q. 
Therefore, down-weighting non-causal variants and up-weighting causal variants could yield 
improved power. In practice, one does not know which variants are causal, so one would set 
√wj = Beta(MAFj; a1, a2), which would be the beta distribution density function with pre-
specified parameters a1 and a2 evaluated at the sample minor-allele frequency (MAF) (across 
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cases and controls combined) for the j-th variant in the data. The Beta density has a distinct 
advantage in being flexible and able to accommodate a wide spectrum of scenarios.  
 SKAT is computationally very efficient. In simulation studies, the length of time to a 
convergent solution depends on the sample size and the number of markers. For 300kb, 3Mb, 
or 3 Gb (the entire genome) on 1000 individuals, the lengths of time were 2.5 seconds, 25 
seconds, and 7 hours, respectively. For the purposes of this study, calculations take seconds 
or a several minutes at worst. Thus, one can see the advantage of this method.  
 SKAT performs a region based testing like burden tests. However, as mentioned 
above, SKAT is a supervised method, so it directly performs multiple regression of a 
phenotype on genotypes for all variants in a region while adjusting for covariates. Thus, as 
with conventional multiple regression models, neither directionality nor magnitudes of the 
associations are assumed beforehand. They are estimated from the data. SKAT has greater 
power than competing burden tests over a range of genetic models. SKAT performs a score-
based variance component test, and the calculation only requires fitting the null model by 
regressing phenotypes on covariates alone and computing p-values analytically. This 
regression framework is rather flexible, and the kernel can be adjusted to allow for epistatic 
effects. SKAT can be applied to any SNP set. Possible phenotype would include outcomes 
such as longitudinal, multivariate, and survival data. The survival data for this study is fit 
through the linear model used for continuous outcomes, as the phenotypes are survival time 
to outcome. In other words, SKAT can be applied to a wide range of sequencing-based 
association studies. Also, because the p-value can be obtained directly without permutation, 
SKAT allows for rapid calculation of the p-values in exome and genome-wide sequencing 
studies.     
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2.3 RNA Expression and Protein Expression Analysis 
 Those genes found to be significant from the full pathway analysis were also verified 
at the RNA and protein expression levels, if such data was available. Among those four 
genes found to be significant from full gene-based pathway analysis (i.e. IL-1, jun proto-
oncogene (c-JUN), evolutionarily conserved signaling intermediate in toll (ECSIT), and 
transforming growth factor beta-activated kinase 1 (TAK1) (please see the results section), 
the analysis at the RNA expression level only includes IL-1, c-JUN, and ECSIT since TAK1 
data was not available. 
The association between the RNA and protein levels and the outcome of survival in 
melanoma was also analyzed via SAS V9.2. The data were drawn from the Cancer Genome 
Atlas (TCGA), which is publicly available at the following website: https://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp. The relevant files for clinical information and 
genotypes for the SNPs and genes were downloaded. The variables of age of diagnosis, 
gender, Clark level, stage, and Breslow index were adjusted for as covariates. The TCGA 
melanoma data was originally derived from M.D. Anderson. I used logistic regression 
analysis to assess relationships due to lack of time-to-event data in TCGA dataset. The odds 
ratio (OR) and the corresponding 95% CI were computed accordingly. 
At the protein level, only c-JUN data was available. In these analyses, c-JUN was 
treated both as a binary variable in one instance (grouped as being above or below the 
median: -1.12 relative units) and a continuous variable in other instance. The results for both 
are provided in the results section. 
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Chapter 3 
Results 
The results are described below for each of the aforementioned three levels of 
analysis. The summary of the results can also be found in the Figure 1 flowchart displayed 
above. 
 
3.1 Individual SNP Analysis for Candidate Gene with External Validation 
Out of 1804 melanoma cases from MDACC dataset, there were only 1543 subjects 
with complete data for the time to event of the three melanoma outcomes and all studied 
covariates . Table 1 illustrates that out of 1543 subjects with complete phenotypic data who 
were included in the anlaysis, 182 subjects (11.8%) died, 269 subjects (17.4%) experienced 
recurrence, and 310 subjects had the composite event of either death and/or recurrence 
(20.1%).  The summary statistics for each of the studied covariates (i.e. gender, age of 
diagnosis, Clark level, tumor stage, and Breslow index) are also presented in Table 1 for the 
subgroup of subjects with or without the event for each of the three studied endpoints. In 
general, for each of the studied endpoints, the percentage of males was higher than females 
for subjects with event of death and/or recurrence compared to those without the event. 
Subjects with events were also older with higher Clark level, more advanced tumor stage, 
and higher Breslow index than those without events. 
It was found that none of the 20 studied candidate SNPs were significantly related to 
time to death.  For the endpoint of recurrence, after adjusting for age at diagnosis, tumor 
stage (III & IV vs. I & I/II), and Clark level (4 & 5 vs. 1, 2, & 3) in the final model, Table 5.2 
suggests borderline significant protective effect for per one ancestral allele copy decrease of 
IL-1 SNPs  rs1800587 (HR [95% CI] = 0.836 [0.694, 1.008], p = 0.061) and rs17561 (HR 
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[95% CI] = 0.835 [0.693, 1.007], p = 0.0588)  on the endpoint of recurrence. Adjusting for 
the same set of covariates in the final model, these two same IL-1 SNPs were significant for 
the composite endpoint of death and/or recurrence, as shown in Table 6.2 with rs1800587 
(HR [95% CI] = 0.823 [0.691, 0.979], p = 0.0283) and rs17561 (HR [95% CI] = 0.821 
[0.690, 0.978], p = 0.027).  
Adjusting for the same set of covariates in the final model (i.e. age at diagnosis, 
tumor stage (III & IV vs. I & I/II), and Clark level (4 & 5 vs. 1, 2, & 3)), among the four 
studied SNPs from TNF-α, two had a borderline significant association with the composite 
endpoint at borderline (Table 6.2). They were rs361525 (HR [95% CI] = 0.707 [0.481, 1.040] 
per one ancestral allele copy decrease, p = 0.0784) and rs1800630 (HR [95% CI] = 1.206 
[0.976, 1.491] per one ancestral allele copy decrease, p = 0.0825). However, per one 
ancestral allele copy decrease of rs361525 seems to provide a protective effect with HR < 1 
and rs1800630 seems to provide harmful effect with HR > 1. Regarding the linkage 
disequilibrium between rs361525 and rs1800630, the percentage came to 0.62%, with a p-
value of 0.0058. As for the minor allele frequencies, they were 0.0587 for rs361525 and 
0.1598 for rs1800630. Table 7.3 for interaction analysis showed borderline significant 
interaction between rs361525 and rs1800630 with a p-value of 0.0652. The nature of the 
interaction of the major alleles for rs361525 and rs1800630 is directional and antagonistic.     
These results were compared to the data from Dr. Florence Demenais' group. As 
mentioned in the methods section, only death outcome data was included in this validation 
analysis as recurrence data was unavailable. Out of 1179 melanoma cases from the French 
dataset, there were only 859 subjects with complete data for the time to death and all studied 
covariates. Out of 859 subjects, 91 subjects (10.6%) died. The mean (SD) of age at first 
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diagnosis was 46.1 (17.9) years of age. This age was lower than that for the MD Anderson 
dataset, and the genders were more evenly distributed with 55.4% for females. The Breslow 
index mean (SD) was 1.5 (2.07). For the Clark level, only 29.9% were in the high level 
category of 4 and 5. The Breslow index and percentage of high Clark level were much lower 
in the French dataset than in the MD Anderson dataset. The French data presented in Table 8 
showed a borderline association of rs3136558 of IL-1 with time to death (HR [95% CI] = 
0.685 [0.011, 42.803], per one ancestral allele copy decrease p = 0.072). Considering the 
wide variation of the hazard ratio, this result is similar to what we found for the insignificant 
association between these SNPs with the death outcome in the analysis of data from 
MDACC. In general, our results were matched with the findings obtained from Dr. 
Demenais’ French dataset. The only discrepancy between our findings and the French results 
are the two following studied SNPs for IL-6: rs180797 and rs1800795. For these two IL-6 
SNPs, the mortality rate was significantly increased by per one ancestral allele copy decrease 
of rs1800797 (HR [95% CI] = 1.495 [1.116, 2.002] p = 0.00683), and rs1800795 (HR [95% 
CI] = 1.501 [1.127, 1.998], p = 0.00545), while our results were not significant for these two 
IL-6 SNPs, being rs1800795 (HR [95% CI] = 0.984 [0.795, 1.218] p = 0.8823) and 
rs1800797 (HR [95% CI] = 1.017 [0.823, 1.256] p = 0.8779). While rs1800797 hazard ratios 
for the MDACC and French data were in the same direction, the hazard ratios of rs1800795 
for the MDACC data were not. I will discuss possible explanations for these differences in 
the discussion section. 
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3.2 Pathway Analysis 
 Table 9 presents the significant results based on the pathway analysis. All the other 
genes described in the methods section that yielded non-significant results are reported in 
table 10, along with the total number of SNPs included in the SKAT analysis. Several genes 
in the IL-1 pathway found to be significant via the SKAT pathway analysis. Overall, 
significant correlation was found between IL-1 and recurrence p = (0.035). Significant 
correlations were also found between ECSIT and the outcome of recurrence (p = 0.02). 
Specifically, c-JUN was found to be highly correlated with recurrence (p = 0.008). Finally, 
there was borderline significant correlation between TAK1 and recurrence (p = 0.074).  
 
3.3 RNA Expression and Protein Expression Analysis 
 To further confirm the DNA results found to be significant from the pathway 
analysis described above, the RNA and protein level analysis was performed based on TCGA 
dataset.  
RNA level data was available for IL-1, ECSIT, and c-JUN. For the RNA level 
analysis, out of 305 subjects from the TCGA dataset, 194 subjects with non-missing data for 
all studied variables were included in this analysis. The rest were missing expression 
outcome or information for age at diagnosis, Clark level, Breslow thickness, tumor stage, or 
gender. The summary statistics of demographics and baseline clinical characteristics are 
presented in Table 11a. The mortality rate was 43.8% (Out of 194 subjects, 85 subjects died).  
In general, subjects died vs. those survived were comparable for all demographics and 
clinical characteristics variables with the exception of Clark level, the percentage of subjects 
with high Clark level 4 & 5 was higher among deaths compared to survivors (69.4% vs. 
52.3%).  
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The unadjusted and adjusted relationships between the mortality rate and each of the 
studied RNA expression levels as a continuous variable are shown in Table 11b and as a 
binary variable for RNA expression level > median vs. <= median in Table 11c respectively. 
Table 11b suggests no significant association between the mortality rate and each of the 
studied RNAs expression levels when treated as continuous variable in both unadjusted and 
adjusted logistic regression analysis.  Similar insignificant results were found when including 
each RNA expression level as binary variable in Table 11c. It could just be that the RNA data 
was sub-optimal. The results in Table 11c illustrate that a higher survival rate was associated 
with a higher IL-1 RNA level above vs. below median of 35 units (Odds ratio (OR) [95% CI] 
= unadjusted: 0.746 [0.422, 1.317] p = 0.3116; adjusted: 0.782 (0.428, 1.430), p = 0.4250).  
The opposite result was found for the ECSIT RNA. A lower survival rate was found for the 
higher ECSIT RNA level above vs. below the median of 670 units (OR [95% CI] = 
unadjusted: 1.134 [0.643, 2.000] p = 0.6643; adjusted 1.083 [0.601, 1.952] p = 0.6643). 
Table 11c shows a trend of higher survival for the higher c-JUN RNA level group, above vs. 
below a median of 1470 units (OR [95% CI] = unadjusted: 0.915 [0.519, 1.614] p = 0.7587; 
adjusted: 0.892 [0.495, 1.607], p = 0.7038). However, all results for the analysis at the RNA 
expression level were insignificant. 
 For the protein level analysis, out of 206 subjects from the TCGA dataset, 119 
subjects with non-missing data for all studied variables were included in this analysis. The 
summary statistics of demographics and baseline clinical characteristics are presented in 
Table 12a. Out of 119 subjects, 55 subjects died with a mortality rate of 46.2%. In general, 
subjects who died were older (mean= 60.9) compared to those who survived (mean = 53.4). 
For all other studied variables, the two groups were comparable. 
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The unadjusted and adjusted relationships between the mortality rate and c-JUN of 
protein expression level as a continuous variable are presented  in Table 12b and as a binary 
variable for protein expression level > vs. <= median of -1.12 units in Table 12c respectively. 
As opposed to the insignificant results for the c-JUN RNA analysis, these two tables showed 
significant results for c-JUN with a trend of higher survival rate for the higher c-JUN protein 
level (above vs. below median of -1.12 units) with an OR [95% CI] = 0.412 [0.189, 0.900] 
and p = 0.0262 in the unadjusted analysis and an OR [95% CI] = 0.417 [0.182, 0.957] and p 
= 0.0390 in the adjusted analysis (Tables 12b).  
The same conclusion was found in Table 12b when c-JUN protein expression level 
was treated as a continuous variable. With an increment of per one unit increase in c-JUN 
protein expression, the OR [95% CI] = 0.405 (0.204, 0.804] with p = 0.0098 for the 
unadjusted analysis, and OR [95% CI] = 0.407 (0.196, 0.844] with p = 0.0156 for the 
adjusted analysis. In these two tables, the odds ratios with the 95% CI for c-JUN protein 
expression level were well below 1. Unfortunately, protein-level data was not available for 
IL-1, ECSIT, and TAK1 so that future analyses will be needed to evaluate these genes that 
were significantly associated with melanoma outcomes in the pathway analysis.  
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Table 1.   Summary Statistics of  Demographics and Vital Status for All Subjects 
    (Total N = 2829) 
 
 
 
Case 
 
Total Number of Subjects (N) 
 
 
1802 
Age of Diagnosis: Years 
  - na 
  - Mean ± SD 
 
 
1802 
52.11 ± 14.52 
Months of follow-upb 
  - na 
  - Mean ± SD 
 
 
1800 
58.54 ± 57.60 
Vital Status 
  - Deaths:  Number of Deaths / N (%) 
 
 
260 / 1802 
(14.43%) 
a n denotes   Number of Subjects   with non-missing data 
b Missing first diagnosis and last diagnosis dates for two subjects in the case group   (Subject 
ID: MN0820 and MN0850) 
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Table 2.1   Frequency Distribution of Subjects with or without Events and Time to 
Event  
                   or Censored for Endpoints:  
- Death,  
- Recurrence,  
- Death and/or Recurrence  
    Among Cases (Total N = 1786a) 
 
 
Endpoint 
 
Event Rate: 
 
 
n (%) 
 
Months from First Diagnosis Date 
to Event or Censored Dateb: 
 
    Mean ± SD               Range                       Medium  
                                   Min – Max                   (IQRc) 
 
 
Alive and without 
Recurrence 
 
1324 (74.13%) 
 
 52.59 ± 
46.39 
 
     0.59  - 526.59 
 
              43.60  
        (24.14, 64.74) 
 
1. Death only 
 
48 (2.69%) 
 
 42.13 ± 
45.99 
 
     3.48  - 233.69 
 
              28.27  
        (14.90, 47.95) 
 
2. Recurrence only 
 
202 (11.31%) 
 
 43.29 ± 
40.35 
 
     1.38  - 192.59 
 
              27.81  
        (12.81, 61.60) 
 
3. Death and Recurrence  
 
212 (11.87%) 
 
 
 40.06 ± 
76.89 
 
     1.02  - 562.00 
 
              17.71  
        (8.16, 37.70) 
 
4. Death regardless of  
    recurrence status 
   (1 + 3) 
 
260 (14.56%) 
 
 
 61.98 ± 
80.35 
 
     3.48  - 625.94 
 
              39.26  
        (20.52, 70.42) 
 
5. Recurrence regardless of  
    vital status (2 + 3)  
 
414 (23.18%) 
 
 
 41.64 ± 
61.77 
 
     1.02  - 562.00 
 
              21.52  
        (9.66, 50.60) 
 
6. Death and/ or Recurrence 
    (1+2+3) 
 
462 (25.87%) 
 
 41.69 ± 
60.28 
 
     1.02  - 562.00 
 
              21.96  
        (10.35, 50.23) 
a   Among 1802 cases, only 1786 subjects were included: 
    - 2 Subjects were excluded due to missing first diagnosis and  
    - 14 subjects were excluded due to missing data for subsequent event assessment  
b Months to Event or Censored  were calculated by (the event or censored date – first diagnosis date) /  30.4375. Where 
censored date = maximum of last diagnosis date and vital status date 
c  IQR denotes  Inter-Quartile Range (i.e. 3rd Quartile – 1st Quartile). 
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Table 2.2    Baseline Demographics and Clinical Characteristics by Subjects with or  without Endpoint of Death, Recurrence, and the     
        Composite Endpoint of Death and / or Recurrence among All Melanoma Cases from MDACC data  
       (Total N = 1543a) 
 
  
Endpoint = Death 
Event Rate = 182 / 1543 
(11.8%) 
 
Endpoint = Recurrence: 
Event Rate = 269 / 1543 
(17.4%) 
Composite Endpoint: 
Death and  / or Recurrence 
Event Rate = 310 / 1543 
(20.1%) 
 All  
Melanoma  
Cases 
 
 
Baseline Demographics & 
Clinical Characteristics 
 
Event 
 (N =182 ) 
 
No Event 
 (N =1361 ) 
 
Event 
 (N =269) 
 
No Event 
( N =1274) 
 
Event 
 (N =310 ) 
 
No Event 
 (N =1233) 
  
 ( N =1543) 
Gender: n (%) 
   - Male 
   - Female 
 
 
129 (70.9%) 
53 (29.1%) 
 
775(56.9%) 
586 (43.1%) 
 
175 (65.1%) 
94 (34.9%) 
 
729 (57.2%) 
545 (42.8%) 
 
207 (66.8%) 
103 (33.2%) 
 
697 (56.5%) 
536 (43.5%) 
  
904 
(58.6%) 
639 
(41.4%) 
Race: n (%) 
   - White 
 
 
182 (100%) 
 
1361 (100%) 
 
269(100%) 
 
1274 (100%) 
 
310 (100%) 
 
1233 (100%) 
  
1543 
(100%) 
Age at First Diagnosis (Years): 
    Mean ± SD 
 
 
59.3  ± 14.6 
 
 
51.4 ± 14.3 
 
 
56.5  ± 14.2 
 
 
51.4 ± 14.5 
 
 
57.4  ± 14.3 
 
 
51.0 ± 14.3 
 
  
52.3 ± 14.5 
 
Stage: n(%) 
   - I & I/II 
   - III & IV 
    
 
39 (21.4%) 
143 (78.6%) 
 
 
913 (67.1%) 
448 (32.9%) 
 
 
66 (24.5%) 
203 (75.5%) 
 
 
886 (69.5%) 
388 (30.5%) 
 
 
83 (26.8%) 
227 (73.2%) 
 
 
869 (70.5%) 
364 (29.5%) 
 
  
952 
(61.7%) 
591 
(38.3%) 
 
Clark level: n(%) 
   - 1, 2, & 3 
   - 4 & 5    
 
51 (28.0%) 
131 (72.0%) 
 
 
769 (56.5%) 
592 43.5%) 
 
 
67 (24.9%) 
202 (75.1%) 
 
 
753 (59.1%) 
521 (40.9%) 
 
 
88 (28.4%) 
222 (71.6%) 
 
 
732 (59.4%) 
501 (40.6%) 
 
  
820 
(53.1%) 
723 
(46.9%) 
 
Breslow Index:  
    Mean ± SD 
     
 
4.03 ± 3.82 
 
 
1.63 ± 2.15 
 
 
3.55 ± 3.37 
 
 
1.57 ± 2.16 
 
 
3.61 ± 3.66 
 
 
1.49 ± 1.93 
 
  
1.92 ± 2.53 
 
       
    a Among 1804 cases, only 1543 subjects with complete data were included. 
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 Table 3.1   Relationship between Age at First Diagnosis and Time to Event or Censored for   
                   Endpoints:  
- Death,  
- Recurrence,  
- Death and/or Recurrence  
    Among Cases  (Total N = 1786a) 
 
 
Endpoint 
 
Age at First Diagnosis:  
 
 Subjects                              Subjects 
with Event:                      without Event: 
 
n      Mean ± SD              n      Mean ± SD 
 
 
 
 
 
Per one Year increase of 
Age at First Diagnosis: 
 
    
 
      Hazard Ratio           p- 
       (95& CI)b            Value b   
 
1. Death regardless of  
    recurrence status 
    
 
260     57.13 ± 14.71 
 
1526     51.27 ± 
14.33      
 
1.039 
(1.029, 1.048) 
 
<0.0001* 
 
2. Recurrence regardless of  
    vital status   
 
414     54.23 ± 14.68 
 
1372     51.49 ± 
14.43      
 
1.021 
(1.013, 1.028) 
 
<0.0001* 
 
3. Death and/ or 
Recurrence 
     
 
462     55.04 ± 14.76 
 
1324     51.11 ± 
14.31      
 
1.025 
(1.018, 1.032) 
 
<0.0001* 
  a Among 1802 cases, only 1786 subjects were included: 
    - 2 Subjects were excluded due to missing first diagnosis and 
    - 14 subjects were excluded due to missing data for subsequent event assessment  
b
 Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values for were based on Wald test from  the  Cox proportional  
   hazard analysis including age at first diagnosis (continuous) as the only variable in the  model   
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Table 3.2         Relationship between Gender  and Time to Event or Censored for Endpoints:  
- Death,  
- Recurrence,  
- Death and/or Recurrence  
    Among Cases  (Total N = 1786a) 
 
 
Endpoint 
 
Event Rate: n / N (%) 
 
        Gender:                             Gender: 
 
          Male                                 Female 
 
 
 
 
Gender: Male vs. Female 
 
    
 
      Hazard Ratio           p- 
       (95& CI)b            Value b   
 
1. Death regardless of  
    recurrence status 
    
 
178 / 1050  
(16.95%) 
 
82 / 736 
(11.14%)  
 
1.583 
(1.218, 2.057) 
 
  0.0006* 
 
2. Recurrence regardless of  
    vital status   
 
265 / 1050  
(25.24%) 
 
149 / 736 
(20.24%)  
 
1.303 
(1.065, 1.593) 
 
  0.0100* 
 
3. Death and/ or 
Recurrence 
     
 
298 / 1050  
(28.38%) 
 
164 / 736 
(22.28%)  
 
1.334 
(1.102, 1.615) 
 
   0.0031* 
  a Among 1802 cases, only 1786 subjects were included: 
    - 2 Subjects were excluded due to missing first diagnosis and 
    - 14 subjects were excluded due to missing data for subsequent event assessment  
b
 Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values for were based on Wald test from  the  Cox proportional  
   hazard analysis including age at first diagnosis (continuous) as the only variable in the  model   
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Table 3.3     Relationship between Stage  and Time to Event or Censored for Endpoints:  
- Death,  
- Recurrence,  
- Death and/or Recurrence  
    Among Cases  (Total N = 1785a) 
 
 
Endpoint 
 
Event Rate: n / N (%) 
 
            Stage:                             Stage: 
 
           I & I/II                         II, III, & IV 
 
 
 
 
Stage II, III &IV   vs. I & 
I/II 
 
      Hazard Ratio           p- 
       (95& CI)b            Value b   
 
1. Death regardless of  
    recurrence status 
    
 
84 / 1095  
(7.67%) 
 
176 / 690 
(25.51%)  
 
4.404 
(3.380, 5.739) 
 
  <.0001* 
 
2. Recurrence regardless of  
    vital status   
 
155 / 1095  
(14.16%) 
 
259 / 690 
(37.54%)  
 
3.572 
(2.921, 4.368) 
 
  <.0001* 
 
3. Death and/ or 
Recurrence 
     
 
174 / 1095  
(15.89%) 
 
288 / 690 
(41.74%)  
 
3.555 
(2.939, 4.299) 
 
   <.0001* 
  a Among 1802 cases, only 1785 subjects were included: 
    - 2 Subjects were excluded due to missing first diagnosis and 
    - 14 subjects were excluded due to missing data for subsequent event assessment  
    - 1 subject with missing data for stage 
b
 Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values for were based on Wald test from  the  Cox proportional  
   hazard analysis including age at first diagnosis (continuous) as the only variable in the  model   
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Table 3.4     Relationship between Clark Level and Time to Event or Censored for Endpoints:  
- Death,  
- Recurrence,  
- Death and/or Recurrence  
    Among Cases  (Total N = 1543a) 
 
 
Endpoint 
 
Event Rate: n / N (%) 
 
         Clark Level:               Clark Level: 
 
             1, 2, &3                          4 & 5 
 
 
 
 
Clark Level: 
4 & 5   vs. 1 , 2, &3 
 
      Hazard Ratio           p- 
       (95& CI)b            Value b   
 
1. Death regardless of  
    recurrence status 
    
 
51 / 820  
(6.22%) 
 
131 / 723 
(18.12%)  
 
3.104 
(2.245, 4.291) 
 
  <.0001* 
 
2. Recurrence regardless of  
    vital status   
 
67 / 820  
(8.17%) 
 
202 / 723 
(27.94%)  
 
3.971 
(3.012, 5.237) 
 
  <.0001* 
 
3. Death and/ or 
Recurrence 
     
 
88 / 820  
(10.73%) 
 
222 / 723 
(30.71%)  
 
3.330 
(2.601, 4.264) 
 
  <.0001* 
  a Among 1802 cases, only 1543 subjects were included: 
    - 2 Subjects were excluded due to missing first diagnosis and 
    - 14 subjects were excluded due to missing data for subsequent event assessment  
    - 243 subjects with missing data for Clark level  
b
 Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values for were based on Wald test from  the  Cox proportional  
   hazard analysis including age at first diagnosis (continuous) as the only variable in the  model   
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Table 4.1   Comparison of Time from First Diagnosis to  Endpoint of Death 
      (Regardless of  Recurrent  Status) among the 3 Allele Types for Each Gene 
      Among Cases  (Total N = 1543a)- Unadjusted Analysis 
 
 Endpoint = Death regardless of  Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
SNP 
 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
 
IL-1 
     
 
rs1800587 
   
 
85 / 733 
(11.60%) 
 
    78 / 665 
(11.73%) 
 
19 / 145 
(13.10%) 
 
1.038 
(0.834, 1.291) 
 
0.7406 
 
rs17561 
 
85 / 733  
(11.60%) 
 
    78 / 665 
(11.73%) 
 
19 / 145 
(13.10%) 
 
1.040 
(0.836, 1.293) 
 
0.7273 
 
rs2071374 
   
 
88 / 776 
(11.34%) 
   
  84 / 663 
(12.67%) 
 
10 / 104 
(9.62%) 
 
1.042 
(0.826, 1.315) 
 
0.7287 
 
rs16944  
 
20 / 155 
 (12.90%) 
     
 89 / 701 
(12.70%) 
 
73 / 687 
(10.63%) 
 
0.891 
(0.714, 1.113) 
 
0.3103 
 
rs1143627 
   
 
20 / 155 
 (12.90%) 
     
 89 / 701 
(12.70%) 
 
73 / 687 
(10.63%) 
 
0.891 
(0.714, 1.113) 
 
0.3103 
 
rs1071676 
  
 
107 / 877 
(12.20%) 
 
66 / 564 
(11.70%) 
 
9 / 102 
(8.82%) 
 
0.943 
(0.742, 1.200) 
 
0.6351 
 
rs1143634 
  
 
107 / 880 
(12.16%) 
 
66 / 564 
(11.70%) 
 
9 / 99 
(9.09%) 
 
0.959 
(0.753, 1.221) 
 
0.7338 
 
rs3136558 
  
 
119 / 955 
(12.46%) 
     
55 / 504  
(10.91) 
    
 8 / 84 
(9.52%) 
 
0.892 
(0.690, 1.152) 
 
0.3807 
IL-6 
 
     
rs1800795 
 
62 / 509 
 (12.18%) 
 
84 / 753  
(11.16%) 
 
36 / 281 
(12.81%) 
1.005 
(0.814, 1.240) 
0.9659 
rs1800797 63 / 530  
(11.89%) 
83 / 743  
(11.17%) 
 36 / 270 
(13.33%) 
1.031 
(0.836, 1.271) 
0.7765 
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Table 4.1   Comparison of Time from First Diagnosis to Endpoint of Death 
(cont’d)     (Regardless of Recurrent Status) among the 3 Allele Types for Each Gene 
      Among Cases (Total N = 1543a)- Unadjusted Analysis 
 
 Endpoint = Death regardless of  Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
SNP 
 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
IL-8      
rs4073 29 / 315  
(9.21%) 
 
100 / 758  
(13.19%) 
 
 53 / 470 
(11.28%) 
1.090 
(0.886, 1.341) 
0.4150 
rs2227307 53 / 483 
 (10.97%) 
 
102 / 754  
(13.53%) 
 
 27 / 306 
(8.82%) 
0.923 
(0.750, 1.136) 
0.4503 
rs2227306 61 / 531 
 (11.49%) 
 
95 / 738  
(12.87%) 
 26 / 274 
(9.49%) 
0.921 
(0.748, 1.134) 
0.4371 
IFN-G      
rs2430561 31 / 321  
(9.66%) 
 
83 / 752  
(11.04%) 
 
 68 / 470 
(14.47%) 
1.227 
(0.995, 1.514) 
0.0559 
rs1861494 19 / 140  
(13.57%) 
 
79 / 640  
(12.34%) 
 
 84 / 763 
(11.01%) 
0.903 
(0.725, 1.125) 
0.3626 
rs2069705 22 / 172  
(12.79%) 
 
86 / 698  
(12.32%) 
 74 / 673 
(11.00%) 
0.914 
(0.737, 1.133) 
0.4125 
TNF-A      
rs361525 169 / 1367 
(12.36%) 
 
13 / 171  
(7.60%) 
 
 0 / 5  
(0.00%) 
0.593 
(0.340, 1.036) 
0.0666 
rs1800629 135 / 1092 
(12.36%) 
 
42 / 408  
(10.29%) 
 
 5 / 43 
(11.63%) 
0.901 
(0.673, 1.205) 
0.4805 
rs1799964 5 / 82 
 (6.10%) 
 
61 / 510  
(11.96%) 
 
116 / 951 
(12.20%) 
1.137 
(0.882, 1.467) 
0.3221 
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rs1800630 127 / 1090 
(11.65%) 
 
52 / 413  
(12.59%) 
 
 3 / 40 
(7.50%) 
1.005 
(0.758, 1.332) 
0.9716 
 a  Among 1802 cases, only 1543 subjects were included: 
   - 2 Subjects were excluded due to missing first diagnosis and 
  - 14 subjects were excluded due to missing data for subsequent event assessment  
 - 1 subject had missing data for both stage and Clark level;  242 subjects had missing data for Clark level 
b 
 Hazard ratios, 95% confidence interval (CI) of hazard ratio, and p-values were based on Wald test from Cox 
proportional  
   hazard analysis  including copies of ancestral allele as the major predictor (continuous scale) . 
   hazard analysis  including number of copies as the major predictor (continuous scale) . 
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Table 4.2   Comparison of Time from First Diagnosis to Endpoint of Death (Regardless of Recurrent Status) among the 3 Allele Types for Each 
SNP Among Cases (Total N = 1543a) - Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death regardless of Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
   SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
IL-1 
              
 
rs1800587 
   
 
85 / 733 
(11.60%) 
 
    78 / 665 
(11.73%) 
 
19 / 145 
(13.10%) 
 
0.948 
(0.759, 1.185) 
 
0.6405 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.962 
(3.369, 7.308) 
 
<.0001* 
 
1.388 
(0.975, 1.975) 
 
0.0688 
 
rs17561 
 
85 / 733 
(11.60%) 
 
    78 / 665 
(11.73%) 
 
19 / 145 
(13.10%) 
 
0.947 
(0.758, 1.183) 
 
0.6297 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.964 
(3.371, 7.311) 
 
<.0001* 
 
1.388 
(0.975, 1.975) 
 
0.0688 
 
rs2071374 
   
 
88 / 776 
(11.34%) 
   
  84 / 663 
(12.67%) 
 
10 / 104 
(9.62%) 
 
1.130 
(0.894, 1.430) 
 
0.3069 
  
1.030 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.970 
(3.374, 7.321) 
 
<.0001* 
 
1.389 
(0.976, 1.976) 
 
0.0679 
 
rs16944 
 
20 / 155 
(12.90%) 
     
 89 / 701 
(12.70%) 
 
73 / 687 
(10.63%) 
 
0.883 
(0.712, 1.095) 
 
0.2569 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.947 
(3.360, 7.285) 
 
<.0001* 
 
1.382 
(0.972, 1.966) 
 
0.0717 
 
rs1143627   
 
20 / 155 
(12.90%) 
 
     89 / 701 
(12.70%) 
 
73 / 687 
(10.63%) 
 
0.883 
(0.712, 1.095) 
 
0.2569 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.947 
(3.360, 7.285) 
 
<.0001* 
 
1.382 
(0.972, 1.966) 
 
0.0717 
 
rs1071676 
  
 
107 / 877 
(12.20%) 
 
    66 / 564 
(11.70%) 
 
9 / 102 
(8.82%) 
 
0.865 
(0.673, 1.112) 
 
0.2591 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.963 
(3.372, 7.305) 
 
<.0001* 
 
1.393 
(0.980, 1.981) 
 
0.0649 
 
rs1143634 
  
 
107 / 880 
(12.16%) 
     
66 / 564 
(11.70%) 
 
9 / 99 
(9.09%) 
 
0.870 
(0.677, 1.119) 
 
0.2792 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.969 
(3.376, 7.315) 
 
<.0001* 
 
1.392 
(0.979, 1.980) 
 
0.0654 
 
rs3136558 
  
 
119 / 955 
(12.46%) 
     
55 / 504  
(10.91%) 
    
 8 / 84 
(9.52%) 
 
0.820 
(0.632, 1.063) 
 
0.1345 
  
1.031 
(1.020, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.973 
(3.379, 7.321) 
 
<.0001* 
 
1.390 
(0.978, 1.976) 
 
0.0665 
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Table 4.2   Comparison of Time from First Diagnosis to  Endpoint of Death  (Regardless of  Recurrent  Status) among the 3 Allele Types for  
(cont’d)    Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death regardless of Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
   SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% 
CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
IL-6               
rs1800795 
 
62 / 509 
(12.18%
) 
 
84 / 753  
(11.16%) 
 
36 / 281 
(12.81%) 
0.984 
(0.795, 1.218) 
0.8823  1.031 
(1.019, 1.042) 
<.0001* -------- ----- 4.952 
(3.361, 7.295) 
<.0001* 1.380 
(0.970, 1.963) 
0.0737 
 
rs1800797 
 
63 / 530 
(11.89%
) 
 
 
83 / 743  
(11.17%) 
 
  
36 / 270 
(13.33%) 
 
1.017 
(0.823, 1.256) 
 
0.8779 
  
1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.943 
(3.355, 7.282) 
 
<.0001* 
 
1.381 
(0.971, 1.965) 
 
0.0729 
IL-8               
rs4073 29 / 315 
(9.21%) 
 
100 / 758  
(13.19%) 
 
 53 / 470 
(11.28%) 
1.048 
(0.852, 1.289) 
0.6584  1.031 
(1.019, 1.042) 
<.0001*  
-------- 
 
----- 
4.927 
(3.344, 7.259) 
<.0001* 1.386 
(0.974, 1.973) 
0.0698 
rs2227307 53 / 483 
(10.97%
) 
 
102 / 754  
(13.53%) 
 
 27 / 306 
(8.82%) 
0.959 
(0.779, 1.180) 
0.6933  1.031 
(1.019, 1.042) 
<.0001*  
-------- 
 
----- 
4.930 
(3.346, 7.263) 
<.0001* 1.385 
(0.973, 1.971) 
0.0704 
rs2227306 61 / 531 
(11.49%
) 
 
95 / 738  
(12.87%) 
 
 26 / 274 
(9.49%) 
0.942 
(0.765, 1.160) 
0.5746  1.031 
(1.019, 1.042) 
<.0001*  
-------- 
 
----- 
4.929 
(3.346, 7.261) 
<.0001* 1.386 
(0.974, 1.972) 
0.0697 
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 Endpoint = Death regardless of Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
   SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% 
CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
IFN-G               
rs2430561 31 / 321 
(9.66%) 
 
83 / 752  
(11.04%) 
 
 68 / 470 
(14.47%) 
1.184 
(0.958, 1.463) 
0.1175  1.031 
(1.020, 1.043) 
 
<.0001* 
 
-------- 
 
----- 
 
4.897 
(3.328, 7.206) 
 
<.0001* 
 
1.391 
(0.979, 1.978) 
 
0.0655 
rs1861494 19 / 140 
(13.57%
) 
 
79 / 640  
(12.34%) 
 
 84 / 763 
(11.01%) 
0.890 
(0.712, 1.113) 
0.3066  1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.929 
(3.347, 7.259) 
 
<.0001* 
 
1.392 
(0.978, 1.981) 
 
0.0660 
rs2069705 22 / 172 
(12.79%
) 
 
86 / 698  
(12.32%) 
 
 74 / 673 
(11.00%) 
0.906 
(0.730, 1.124) 
0.3694  1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.931 
(3.348, 7.263) 
 
<.0001* 
 
1.390 
(0.977, 
1.978) 
 
0.0672 
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Table 4.2   Comparison of Time from First Diagnosis to Endpoint of Death (Regardless of Recurrent Status) among the 3 Allele Types for  
(cont’d)    Each SNP Among Cases (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death regardless of Recurrent Status 
Total Mortality Rate = 182 / 1543 (11.80%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
   SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
value
b
 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
TNF-A               
rs361525 169 / 1367 
(12.36%) 
 
13 / 171  
(7.60%) 
 
 0 / 5 
(0.00%) 
0.614 
(0.353, 1.066) 
0.0832  1.030 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.964 
(3.370, 7.310) 
 
<.0001* 
 
1.373 
(0.965, 1.955) 
 
0.0782 
rs1800629 135 / 1092 
(12.36%) 
 
42 / 408  
(10.29%) 
 
 5 / 43 
(11.63%) 
0.954 
(0.715, 1.274) 
0.7510  1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.934 
(3.348, 7.270) 
 
<.0001* 
 
1.382 
(0.971, 1.966) 
 
0.0723 
rs1799964 5 / 82 
 (6.10%) 
 
61 / 510  
(11.96%) 
 
116 / 951 
(12.20%) 
0.997 
(0.775, 1.281) 
0.9786  1.031 
(1.019, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
4.948 
(3.357, 7.294) 
 
<.0001* 
 
1.381 
(0.970, 1.964) 
 
0.0731 
rs1800630 127 / 1090 
(11.65%) 
 
52 / 413  
(12.59%) 
 
 3 / 40 
(7.50%) 
1.190 
(0.898, 1.577) 
0.2248  1.031 
(1.020, 1.042) 
 
<.0001* 
 
-------- 
 
----- 
 
5.046 
(3.423, 7.439) 
 
<.0001* 
 
1.372 
(0.965, 1.952) 
 
0.0782 
a Among 1802 cases, only 1543 subjects were included: 
  2 Subjects were excluded due to missing first diagnosis,   14 subjects were excluded due to missing data for subsequent event assessment, and 243 subjects were excluded due to missing data of age, gender, stage, and Clark 
level       
b Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values were based on  the Wald test from a Cox proportional hazard model built by stepwise selection process by forcing  the copies  of ancestral allele as 
the major  predictor (continuous scale) and  the remaining covariates (age at diagnosis , gender, stage, and Clark level ) were selected by stepwise process using significant level of 0.10 to be  entered and kept in the final 
model. 
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Table 5.1   Comparison of Time from First Diagnosis to  Endpoint of Recurrence 
      (Regardless of  Vital  Status) among the 3 Allele Types for Each Gene 
      Among Cases  (Total N = 1543a)- Unadjusted Analysis 
 
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543 (17.43%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
 
IL-1 
     
 
rs1800587: 
   
 
135 / 733 
(18.42%) 
 
111 / 665 
(16.69%) 
 
23 / 145 
(15.86%) 
 
0.919 
(0.763, 1.105) 
 
0.3685 
 
rs17561: 
 
135 / 733 
(18.42%) 
 
111 / 665 
(16.69%) 
 
23 / 145 
(15.86%) 
 
0.920 
(0.764, 1.107) 
 
0.3766 
 
rs2071374: 
   
 
135 / 776 
(17.40%) 
   
 122 / 663 
(18.40%) 
 
12 / 104 
(11.54%) 
 
0.958 
(0.789, 1.163) 
 
0.6620 
 
rs16944:  
 
26 / 155 
 (16.77%) 
     
136 / 701 
(19.40%) 
 
107 / 687 
(15.57%) 
 
0.910 
(0.759, 1.091) 
 
0.3084 
 
rs1143627: 
   
 
26 / 155 
 (16.77%) 
     
136 / 701 
(19.40%) 
 
107 / 687 
(15.57%) 
 
0.910 
(0.759, 1.091) 
 
0.3084 
 
rs1071676: 
  
 
152 / 877 
(17.33%) 
 
   102 / 564 
(18.09%) 
 
15 / 102 
(14.71%) 
 
1.018 
(0.840, 1.234) 
 
0.8565 
 
rs1143634: 
  
 
152 / 880 
(17.27%) 
     
102 / 564 
(18.09%) 
 
15 / 99 
(15.15%) 
 
1.036 
(0.853, 1.257) 
 
0.7213 
 
rs3136558: 
  
 
174 / 955 
(18.22%) 
 
     
81 / 504  
(16.07%) 
 
    
14 / 84 
(16.67%) 
 
0.928 
(0.755, 1.140) 
 
0.4756 
 
IL-6 
     
rs1800795 
 
89 / 509 
 (17.49%) 
 
136 / 753  
(18.06%) 
 
44 / 281 
(15.66%) 
0.958 
(0.807, 1.138) 
0.6280 
rs1800797 95 / 530 
 (17.92%) 
 
131 / 743  
(17.63%) 
 
 43 / 270 
(15.93%) 
0.945 
(0.796, 1.123) 
0.5233 
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Table 5.1   Comparison of Time from First Diagnosis to  Endpoint of Recurrence 
(cont’d)     (Regardless of  Vital  Status) among the 3 Allele Types for Each Gene 
      Among Cases  (Total N = 1543a)- Unadjusted Analysis 
 
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543 (17.43%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
 
IL-8 
     
rs4073 48 / 315  
(15.24%) 
 
142 / 758  
(18.73%) 
 
 79 / 470 
(16.81%) 
1.040 
(0.879, 1.231) 
0.6439 
rs2227307 80 / 483 
 (16.56%) 
 
143 / 754  
(18.97%) 
 
 46 / 306 
(15.03%) 
0.969 
(0.819, 1.146) 
0.7113 
rs2227306 88 / 531 
 (16.57%) 
141 / 738  
(19.11%) 
 40 / 274 
(14.60%) 
0.962 
(0.813, 1.140) 
0.6571 
 
IFN-G 
     
rs2430561 49 / 321 
 (15.26%) 
 
126 / 752  
(16.76%) 
 
 94 / 470 
(20.00%) 
1.142 
(0.962, 1.356) 
0.1280 
rs1861494 27 / 140  
(19.29%) 
 
112 / 640  
(17.50%) 
 
 130 / 763 
(17.04%) 
0.970 
(0.808, 1.164) 
0.7399 
rs2069705 33 / 172  
(19.19%) 
122 / 698  
(17.48%) 
 114 / 673 
(16.94%) 
0.966 
(0.809, 1.154) 
0.7045 
 
TFN-A 
     
rs361525 246 / 1367 
(18.00%) 
 
22 / 171  
(12.87%) 
 
 1 / 5 
(20.00%) 
0.727 
(0.482, 1.096) 
0.1282 
rs1800629 191 / 1092 
(17.49%) 
 
69 / 408  
(16.91%) 
 
 9 / 43 
(20.93%) 
1.017 
(0.810, 1.277) 
0.8862 
rs1799964 13 / 82 
(15.85%) 
 
90 / 510  
(17.65%) 
 
 166 / 951 
(17.46%) 
1.025 
(0.837, 1.255) 
0.8111 
rs1800630 186 / 1090 
(17.06%) 
74 / 413  
(17.92%) 
 9 / 40 
(22.50%) 
1.085 
(0.866, 1.360) 
0.4756 
 a  Among 1802 cases, only 1543 subjects were included: 
   - 2 Subjects were excluded due to missing first diagnosis  and 
  - 14 subjects were excluded due to missing data for subsequent event assessment  
 - 1 subject had missing data for both stage and Clark level;  242 subjects had missing data for Clark level 
b 
 Hazard ratios, 95% confidence interval (CI) of hazard ratio, and p-values were based on Wald test from Cox 
proportional    hazard analysis  including copies of ancestral allele as the major predictor (continuous scale) . 
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Table 5.2   Comparison of Time from First Diagnosis to  Endpoint of Recurrence (Regardless of  Vital  Status) among the 3 Allele Types 
for Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543 (17.43%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
  SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
IL-1 
              
 
rs1800587 
   
 
135 / 733 
(18.42%) 
 
111 / 665 
(16.69%) 
 
23 / 145 
(15.86%) 
 
0.836 
(0.694, 1.008) 
 
0.0610 
  
1.014 
(1.005, 1.023) 
 
0.0020* 
 
-------- 
 
----- 
 
4.160 
(3.062, 5.652) 
 
<.0001* 
 
2.010 
(1.483, 
2.725) 
 
<.0001* 
 
rs17561 
 
135 / 733 
(18.42%) 
 
111 / 665 
(16.69%) 
 
23 / 145 
(15.86%) 
 
0.835 
(0.693, 1.007) 
 
0.0588 
  
1.014 
(1.005, 1.023) 
 
0.0020* 
 
-------- 
 
----- 
 
4.165 
(3.065, 5.658) 
 
<.0001* 
 
2.009 
(1.482, 
2.723) 
 
<.0001* 
 
rs2071374 
   
 
135 / 776 
(17.40%) 
   
 122 / 663 
(18.40%) 
 
12 / 104 
(11.54%) 
 
1.061 
(0.871, 1.291) 
 
0.5567 
  
1.014 
(1.005, 1.023) 
 
0.0020* 
 
-------- 
 
----- 
 
4.131 
(3.038, 5.617) 
 
<.0001* 
 
1.990 
(1.467, 
2.699) 
 
<.0001* 
 
rs16944 
 
26 / 155 
(16.77%) 
     
136 / 701 
(19.40%) 
 
107 / 687 
(15.57%) 
 
0.907 
(0.760, 1.082) 
 
0.2779 
  
1.014 
(1.005, 1.023) 
 
0.0022* 
 
-------- 
 
----- 
 
4.120 
(3.031, 5.600) 
 
<.0001* 
 
1.985 
(1.464, 
2.692) 
 
<.0001* 
 
rs1143627   
 
26 / 155 
(16.77%) 
     
136 / 701 
(19.40%) 
 
107 / 687 
(15.57%) 
 
0.907 
(0.760, 1.082) 
 
0.2779 
  
1.014 
(1.005, 1.023) 
 
0.0022* 
 
-------- 
 
----- 
 
4.120 
(3.031, 5.600) 
 
<.0001* 
 
1.985 
(1.464, 
2.692) 
 
<.0001* 
 
rs1071676 
  
 
152 / 877 
(17.33%) 
 
   102 / 564 
(18.09%) 
 
15 / 102 
(14.71%) 
 
0.959 
(0.784, 1.171) 
 
0.6792 
  
1.014 
(1.005, 1.023) 
 
0.0019* 
 
-------- 
 
----- 
 
4.119 
(3.030, 5.599) 
 
<.0001* 
 
1.988 
(1.466, 
2.695) 
 
<.0001* 
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rs1143634 
  
152 / 880 
(17.27%) 
102 / 564 
(18.09%) 
15 / 99 
(15.15%) 
0.966 
(0.790, 1.181) 
0.7341 1.014 
(1.005, 1.023) 
0.0020* -------- ----- 4.120 
(3.031, 5.601) 
<.0001* 1.987 
(1.465, 
2.694) 
<.0001* 
 
rs3136558 
  
 
174 / 955 
(18.22%) 
 
     
81 / 504  
(16.07%) 
 
    
14 / 84 
(16.67%) 
 
0.863 
(0.699, 1.065) 
 
0.1686 
  
1.014 
(1.005, 1.023) 
 
0.0018* 
 
-------- 
 
----- 
 
4.142 
(3.047, 5.631) 
 
<.0001* 
 
1.986 
(1.465, 
2.693) 
 
<.0001* 
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Table 5.2(cont’d)   Comparison of Time from First Diagnosis to  Endpoint of Recurrence (Regardless of  Vital  Status) among the 3 Allele 
Types for  Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543 (17.43%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
  SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
IL-6               
 
rs1800795 
 
89 / 509 
(17.49%) 
 
136 / 753  
(18.06%) 
 
44 / 281 
(15.66%) 
0.938 
(0.790, 1.113) 
0.4629  1.014 
(1.005, 1.023) 
0.0019* -------- ----- 4.131 
(3.039, 5.615) 
<.0001* 1.980 
(1.460, 
2.685) 
<.0001* 
 
rs1800797 
 
95 / 530 
(17.92%) 
 
 
131 / 743  
(17.63%) 
 
 
 43 / 270 
(15.93%) 
 
0.931 
(0.785, 1.105) 
 
0.4123 
  
1.014 
(1.005, 1.023) 
 
0.0019* 
 
-------- 
 
----- 
 
4.128 
(3.037, 5.610) 
 
<.0001* 
 
1.981 
(1.461, 
2.686) 
 
<.0001* 
IL-8               
rs4073 48 / 315 
(15.24%) 
 
142 / 758  
(18.73%) 
 
 79 / 470 
(16.81%) 
1.021 
(0.863, 1.207) 
0.8091  1.014 
(1.005, 1.023) 
0.0021*  
-------- 
 
----- 
4.110 
(3.024, 5.588) 
<.0001* 1.988 
(1.466, 
2.696) 
<.0001* 
rs2227307 80 / 483 
(16.56%) 
 
143 / 754  
(18.97%) 
 
 46 / 306 
(15.03%) 
0.984 
(0.832, 1.165) 
0.8545  1.014 
(1.005, 1.023) 
0.0021*  
-------- 
 
----- 
4.112 
(3.025, 5.590) 
<.0001* 1.987 
(1.465, 
2.695) 
<.0001* 
rs2227306 88 / 531 
(16.57%) 
 
141 / 738  
(19.11%) 
 
 40 / 274 
(14.60%) 
0.963 
(0.813, 1.141) 
0.6618  1.014 
(1.005, 1.023) 
0.0021*  
-------- 
 
----- 
4.110 
(3.024, 5.587) 
<.0001* 1.990 
(1.467, 
2.699) 
<.0001* 
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Table 5.2(cont’d)   Comparison of Time from First Diagnosis to  Endpoint of Recurrence (Regardless of  Vital  Status) among the 
  3 Allele Types  for Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process
   
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543 (17.43%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 vs. 
1, 2, 3 
Gene 
  SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
IFN-G               
rs2430561 49 / 321 
(15.26%) 
 
126 / 752  
(16.76%) 
 
 94 / 470 
(20.00%) 
1.116 
(0.940, 1.324) 
0.2088  1.014 
(1.005, 1.023) 
0.0019*  
-------- 
 
----- 
4.107 
(3.024, 5.579) 
<.0001* 1.990 
(1.468, 
2.697) 
<.0001* 
rs1861494 27 / 140 
(19.29%) 
 
112 / 640  
(17.50%) 
 
 130 / 
763 
(17.04%) 
0.943 
(0.784, 1.134) 
0.5327  1.014 
(1.005, 1.023) 
0.0020*  
-------- 
 
----- 
4.117 
(3.029, 5.595) 
<.0001* 1.990 
(1.468, 
2.699) 
<.0001* 
rs2069705 33 / 172 
(19.19%) 
 
122 / 698  
(17.48%) 
 
 114 / 
673 
(16.94%) 
0.944 
(0.789, 1.128) 
0.5241  1.014 
(1.005, 1.023) 
0.0021*  
-------- 
 
----- 
4.117 
(3.029, 5.595) 
<.0001* 1.989 
(1.467, 
2.698) 
<.0001* 
TNF-A               
rs361525 246 / 1367 
(18.00%) 
 
22 / 171  
(12.87%) 
 
 1 / 5 
(20.00%) 
0.721 
(0.479, 1.086) 
0.1172  1.014 
(1.005, 1.022) 
0.0025*  
-------- 
 
----- 
4.120 
(3.030, 5.600) 
<.0001* 1.989 
(1.467, 
2.699) 
<.0001* 
rs1800629 191 / 1092 
(17.49%) 
 
69 / 408  
(16.91%) 
 
 9 / 43 
(20.93%) 
1.098 
(0.880, 1.370) 
0.4070  1.014 
(1.005, 1.023) 
0.0022*  
-------- 
 
----- 
4.140 
(3.045, 5.629) 
<.0001* 1.986 
(1.465, 
2.693) 
<.0001* 
rs1799964 13 / 82 
(15.85%) 
 
90 / 510  
(17.65%) 
 
 166 / 
951 
(17.46%) 
0.944 
(0.773, 1.153) 
0.5737  1.014 
(1.005, 1.023) 
0.0018*  
-------- 
 
----- 
4.137 
(3.042, 5.625) 
<.0001* 1.980 
(1.460, 
2.685) 
<.0001* 
rs1800630 186 / 1090 
(17.06%) 
 
74 / 413  
(17.92%) 
 
 9 / 40 
(22.50%) 
1.220 
(0.974, 1.527) 
0.0832  1.014 
(1.005, 1.023) 
0.0014*  
-------- 
 
----- 
4.200 
(3.088, 5.713) 
<.0001* 1.967 
(1.451, 
2.667) 
<.0001* 
a Same as table 4.2  
b Same as table 4.2 
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Table 6.1   Comparison of Time from First Diagnosis to the Composite Endpoint of  
       Death and/ or Recurrence among the 3 Allele Types for Each Gene 
      Among Cases  (Total N = 1543a)- Unadjusted Analysis 
 
 Composite Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
  SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
 
IL-1 
     
 
rs1800587: 
   
 
158 / 733 
(21.56%) 
 
126 / 665 
(18.95%) 
 
26 / 145 
(17.93%) 
 
0.893 
(0.751, 1.062) 
 
0.1996 
 
rs17561: 
 
158 / 733 
(21.56%) 
 
126 / 665 
(18.95%) 
 
26 / 145 
(17.93%) 
 
0.894 
(0.752, 1.063) 
 
0.2060 
 
rs2071374: 
   
 
149 / 776 
(19.20%) 
   
 145 / 663 
(21.87%) 
 
16 / 104 
(15.38%) 
 
1.035 
(0.866, 1.237) 
 
0.7039 
 
rs16944:  
 
28 / 155  
(18.06%) 
     
157 / 701 
(22.40%) 
 
125 / 687 
(18.20%) 
 
0.934 
(0.788 1.107) 
 
0.4309 
 
rs1143627: 
   
 
28 / 155  
(18.06%) 
     
157 / 701 
(22.40%) 
 
125 / 687 
(18.20%) 
 
0.934 
(0.788 1.107) 
 
0.4309 
 
rs1071676: 
  
 
179 / 877 
(20.41%) 
 
115 / 564 
(20.39%) 
 
16 / 102 
(15.69%) 
 
0.969 
(0.809, 1.162) 
 
0.7376 
 
rs1143634: 
  
 
179 / 880 
(20.34%) 
 
115 / 564 
(20.39%) 
 
16 / 99  
(16.16%) 
 
0.985 
(0.821, 1.183) 
 
0.8747 
 
rs3136558: 
  
 
199 / 955 
(20.84%) 
 
     
96 / 504  
(19.05%) 
 
 
15 / 84 
(17.86%) 
 
0.928 
(0.766, 1.124) 
 
0.4442 
 
IL-6 
     
rs1800795 
 
103 / 509 
(20.24%) 
 
154 / 753  
(20.45%) 
 
53 / 281 
(18.86%) 
0.972 
(0.828, 1.141) 
0.7263 
rs1800797 109 / 530 
(20.57%) 
 
149 / 743  
(20.05%) 
 
52 / 270 
(19.26%) 
0.965 
(0.822, 1.133) 
0.6657 
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Table 6.1   Comparison of Time from First Diagnosis to the Composite Endpoint of  
(cont’d)      Death and/ or Recurrence among the 3 Allele Types for Each Gene 
      Among Cases  (Total N = 1543a)- Unadjusted Analysis 
 
 
 Composite Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Unadjusted Analysis 
 
 
Event Rate: n / N (%) 
 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
Gene 
  SNP 
2 copies 1 copy 0 copy Hazard Ratio 
(95% CI) 
 P-valueb 
 
IL-8 
     
rs4073 51 / 315 
 (16.19%) 
 
167 / 758  
(22.03%) 
 
 92 / 470 
(19.57%) 
1.075 
(0.919, 1.258) 
0.3662 
rs2227307 93 / 483 
 (19.25%) 
 
168 / 754  
(22.28%) 
 
 49 / 306 
(16.01%) 
0.940 
(0.803, 1.100) 
0.4395 
rs2227306 106 / 531 
(19.96%) 
161 / 738  
(21.82%) 
 43 / 274 
(15.69%) 
0.915 
(0.781, 1.072) 
0.2700 
 
IFN-G 
     
rs2430561 55 / 321 
 (17.13%) 
 
147 / 752  
(19.55%) 
 
 108 / 470 
(22.98%) 
1.152 
(0.981, 1.352) 
0.0843 
rs1861494 29 / 140 
 (20.71%) 
 
130 / 640  
(20.31%) 
 
 151 / 763 
(19.79%) 
0.996 
(0.840, 1.182) 
0.9643 
rs2069705 35 / 172 
 (20.35%) 
143 / 698  
(20.49%) 
 132 / 673 
(19.61%) 
0.992 
(0.840, 1.172) 
0.9257 
 
TNF-A 
     
rs361525 284 / 1367 
(20.78%) 
 
25 / 171  
(14.62%) 
 
1 / 5 
(20.00%) 
0.703 
(0.477, 1.036) 
0.0751 
rs1800629 224 / 1092 
(20.51%) 
 
77 / 408  
(18.87%) 
 
9 / 43 
 (20.93%) 
0.953 
(0.767, 1.184) 
0.6662 
rs1799964 13 / 82  
(15.85%) 
 
105 / 510  
(20.59%) 
 
192 / 951 
(20.19%) 
1.054 
(0.872, 1.274) 
0.5884 
rs1800630 215 / 1090 
(19.72%) 
86 / 413  
(20.82%) 
9 / 40 
 (22.50%) 
1.059 
(0.857, 1.309) 
0.5929 
   - 2 Subjects were excluded due to missing first diagnosis  and 
  - 14 subjects were excluded due to missing data for subsequent event assessment  
 - 1 subject had missing data for both stage and Clark level;  242 subjects had missing data for Clark level 
b 
 Hazard ratios, 95% confidence interval (CI) of hazard ratio, and p-values were based on Wald test from Cox 
proportional  
   hazard analysis  including copies of ancestral allele as the major predictor (continuous scale) . 
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Table 6.2   Comparison of Time from First Diagnosis to the Composite Endpoint of Death  and / or Recurrent among the 3 
Allele Types for Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death and/or  Recurrent  
Total EventRate = 310 / 1543 (20.09%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year 
Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 
vs. 
1, 2, 3 
Gene 
SNP 
2 copies 1 copy 0 copy Hazard 
Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% 
CI)b 
 P-
value
b
 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
IL-1 
              
 
rs1800587 
   
 
158 / 733 
(21.56%) 
 
126 / 665 
(18.95%) 
 
26 / 145 
(17.93%) 
 
0.823 
(0.691, 
0.979) 
 
0.0283
* 
  
1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.934 
(2.973, 
5.206) 
 
<.0001
* 
 
1.683 
(1.280, 
2.212) 
 
0.0002
* 
 
rs17561 
 
158 / 733 
(21.56%) 
 
126 / 665 
(18.95%) 
 
26 / 145 
(17.93%) 
 
0.821 
(0.690, 
0.978) 
 
0.0270
* 
  
1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.939 
(2.977, 
5.213) 
 
<.0001
* 
 
1.681 
(1.279, 
2.210) 
 
0.0002
* 
 
rs2071374 
   
 
149 / 776 
(19.20%) 
   
 145 / 663 
(21.87%) 
 
16 / 104 
(15.38%) 
 
1.139 
(0.951, 
1.364) 
 
0.1577 
  
1.020 
(1.011, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.927 
(2.964, 
5.202) 
 
<.0001
* 
 
1.670 
(1.270, 
2.196) 
 
0.0002
* 
 
rs16944 
 
28 / 155 
(18.06%) 
     
157 / 701 
(22.40%) 
 
125 / 687 
(18.20%) 
 
0.934 
(0.792 1.103) 
 
0.4225 
  
1.020 
(1.011, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.893 
(2.940, 
5.155) 
 
<.0001
* 
 
1.660 
(1.262, 
2.183) 
 
0.0003
* 
 
rs1143627   
 
28 / 155 
(18.06%) 
     
157 / 701 
(22.40%) 
 
125 / 687 
(18.20%) 
 
0.934 
(0.792 1.103) 
 
0.4225 
  
1.020 
(1.011, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.893 
(2.940, 
5.155) 
 
<.0001
* 
 
1.660 
(1.262, 
2.183) 
 
0.0003
* 
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rs1071676 
  
179 / 877 
(20.41%) 
115 / 564 
(20.39%) 
16 / 102 
(15.69%) 
0.914 
(0.757, 
1.104) 
0.3505 1.020 
(1.012, 
1.029) 
<.0001
* 
-------- ----- 3.898 
(2.944, 
5.161) 
<.0001
* 
1.665 
(1.266, 
2.189) 
0.0003
* 
 
rs1143634 
  
 
179 / 880 
(20.34%) 
 
115 / 564 
(20.39%) 
 
16 / 99  
(16.16%) 
 
0.921 
(0.762, 
1.113) 
 
0.3930 
  
1.020 
(1.012, 
1.029) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.901 
(2.946, 
5.165) 
 
<.0001
* 
 
1.664 
(1.266, 
2.188) 
 
0.0003
* 
 
rs3136558 
  
 
199 / 955 
(20.84%) 
 
     
96 / 504  
(19.05%) 
 
 
15 / 84 
(17.86%) 
 
0.868 
(0.714, 
1.054) 
 
0.1533 
  
1.020 
(1.012, 
1.029) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.912 
(2.955, 
5.180) 
 
<.0001
* 
 
1.662 
(1.264, 
2.185) 
 
0.0003
* 
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Table 6.2(cont’d)   Comparison of Time from First Diagnosis to the Composite Endpoint of Death  and / or Recurrent among the 3  
  Allele Types for  Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year 
Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 
vs. 
1, 2, 3 
Gene 
SNP 
2 copies 1 copy 0 copy Hazard 
Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% 
CI)b 
 P-
value
b
 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
IL-6 
              
rs1800795 103 / 509 
(20.24%) 
154 / 753 
(20.45%)  
53 / 281 
(18.86%) 
0.949 
(0.808, 
1.114) 
0.5187  1.020 
(1.012, 
1.029) 
<.0001
* 
-------- ----- 3.903 
(2.947, 
5.167) 
<.0001
* 
1.658 
(1.261, 
2.180) 
0.0003
* 
rs1800797 109 / 530 
(20.57%) 
 
149 / 743  
(20.05%) 
 
 52 / 270 
(19.26%) 
0.948 
(0.807, 
1.112) 
0.5096  1.020 
(1.012, 
1.029) 
<.0001
* 
-------- ----- 3.899 
(2.945, 
5.162) 
<.0001
* 
1.659 
(1.261, 
2.181) 
0.0003
* 
 
IL-8 
              
rs4073 51 / 315 
(16.19%) 
 
167 / 758  
(22.03%) 
 
 92 / 470 
(19.57%) 
1.051 
(0.898, 
1.229) 
0.5348  1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.880 
(2.931, 
5.138) 
 
<.0001
* 
 
1.666 
(1.267, 
2.191) 
 
0.0003
* 
rs2227307 93 / 483 
(19.25%) 
 
168 / 754  
(22.28%) 
 
 49 / 306 
(16.01%) 
0.958  
(0.819, 
1.121) 
0.5960  1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.883 
(2.932, 
5.141) 
 
<.0001
* 
 
1.665 
(1.266, 
2.189) 
 
0.0003
* 
rs2227306 106 / 531 
(19.96%) 
 
161 / 738  
(21.82%) 
 
 43 / 274 
(15.69%) 
0.920 
(0.785, 
1.079) 
0.3042  1.020 
(1.011, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.881 
(2.932, 
5.139) 
 
<.0001
* 
 
1.669 
(1.269, 
2.195) 
 
0.0002
* 
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IFN-G 
              
rs2430561 55 / 321 
(17.13%) 
 
147 / 752  
(19.55%) 
 
 108 / 
470 
(22.98%) 
1.127 
(0.960, 
1.323) 
0.1428  1.020 
(1.012, 
1.029) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.882 
(2.934, 
5.136) 
 
<.0001
* 
 
1.666 
(1.268, 
2.189) 
 
0.0003
* 
rs1861494 29 / 140 
(20.71%) 
 
130 / 640  
(20.31%) 
 
 151 / 
763 
(19.79%) 
0.970 
(0.816, 
1.153) 
0.7280  1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.890 
(2.938, 
5.150) 
 
<.0001
* 
 
1.664 
(1.265, 
2.189) 
 
0.0003
* 
rs2069705 35 / 172 
(20.35%) 
 
143 / 698  
(20.49%) 
 
 132 / 
673 
(19.61%) 
0.969 
(0.820, 
1.146) 
0.7163  1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.890 
(2.938, 
5.150) 
 
<.0001
* 
 
1.664 
(1.265, 
2.188) 
 
0.0003
* 
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Table 6.2(cont’d)   Comparison of Time from First Diagnosis to the Composite Endpoint of Death  and / or Recurrent among the 3 
Allele Types for  Each SNP Among Cases  (Total N = 1543a)- Final Model Built by Stepwise Selection Process 
 
 Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Final Model: by Stepwise Selection process 
     
Covariates: Entered into the final model by step-wise selection process: 
 
 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
 
 
Ancestral Allele: 
Per 1 copy decrease 
 
  
Age at First DX. 
Per 1 Year 
Increase 
 
Gender: 
Male vs. Female 
 
Stage III & IV vs. 
I & I/II 
 
Clark Level  4 & 5 
vs. 
1, 2, 3 
Gene 
SNP 
2 copies 1 copy 0 copy Hazard 
Ratio 
(95% CI)b 
 P-
valueb 
 Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% 
CI)b 
 P-
value
b
 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
Hazard  
Ratio 
(95% CI)b 
 P-
valueb 
 
TNF-A 
              
rs361525 284 / 1367 
(20.78%) 
 
25 / 171  
(14.62%) 
 
 1 / 5 
(20.00%) 
0.707 
(0.481, 
1.040) 
0.0784  1.020 
(1.011, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.898 
(2.944, 
5.162) 
 
<.0001
* 
 
1.661 
(1.263, 
2.186) 
 
0.0003
* 
rs1800629 224 / 1092 
(20.51%) 
 
77 / 408  
(18.87%) 
 
 9 / 43 
(20.93%) 
1.023 
(0.827, 
1.265) 
0.8354  1.020 
(1.012, 
1.028) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.896 
(2.941, 
5.161) 
 
<.0001
* 
 
1.661 
(1.263, 
2.185) 
 
0.0003
* 
rs1799964 13 / 82 
(15.85%) 
 
105 / 510  
(20.59%) 
 
 192 / 
951 
(20.19%) 
0.958 
(0.795, 
1.156) 
0.6560  1.020 
(1.012, 
1.029) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.905 
(2.948, 
5.174) 
 
<.0001
* 
 
1.659 
(1.262, 
2.182) 
 
0.0003
* 
rs1800630 215 / 1090 
(19.72%) 
 
86 / 413  
(20.82%) 
 
 9 / 40 
(22.50%) 
1.206 
(0.976, 
1.491) 
0.0825  1.020 
(1.012, 
1.029) 
 
<.0001
* 
 
-------- 
 
----- 
 
3.969 
(2.996, 
5.259) 
 
<.0001
* 
 
1.650 
(1.255, 
2.169) 
 
0.0003
* 
a Among 1802 cases, only 1543 subjects were included: 
  2 Subjects were excluded due to missing first diagnosis, 14 subjects were excluded due to missing data for subsequent event assessment, and  243 subjects were excluded due to missing data of age, 
gender, stage, and Clark level       
b Hazard ratios, 95% confidence interval (CI) of hazard ratio, and p-values were based on the Wald test from a Cox proportional hazard model built by stepwise selection process by forcing  the copies  
of ancestral allele as the major  predictor (continuous scale) and  the remaining covariates (age at diagnosis , gender, stage, and Clark level ) were selected by stepwise process using significant level of 
0.10 to be  entered and kept in the final model 
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Table 7.1 Interaction of IL-1 SNPs rs1800587 and rs7561 for Outcome of Death 
 Endpoint = Recurrence regardless of  Vital Status 
Total Event Rate = 269 / 1543a (17.43%) 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
  
 
Ancestral Allele on 
Individual SNP: 
Per 1 copy decrease 
 
 
 
Interaction 
between  
2 SNPs 
Individual   
SNP: 
2 copies 1 copy 0 copies Hazard Ratio 
(95% CI)b 
 P-
valueb 
P- 
valuec 
  IL-1 
  rs1800587 
 
135 / 733  
(18.42%) 
 
111 / 665  
(16.69%) 
 
23 / 145  
(15.86%) 
 
0.836 
(0.694, 1.008) 
 
0.0610 
 
  IL-1 
  rs17561 
 
135 / 733 
(18.42%) 
 
111 / 665  
(16.69%) 
 
 
23 / 145 
(15.86%) 
 
 
0.835 
(0.693, 1.007) 
 
0.0588 
 
Combination of 
2 SNPs: 
 
   IL-1  rs1800587  
   And 
 
 
  
2 copies 
 
 
 
1 copy 
 
 
 
0 copies 
   
   
   IL-1 rs7561 
 
 
2  
copies 
 
1 
 copy  
 
0 
copy 
 
2  
copies 
 
1 
copy  
 
0  
copy 
 
2  
copies 
 
1  
copy  
 
0 
 copy 
   
  
135/732 
(18.44%) 
 
0 / 1 
(0%) 
 
 
0 / 0  
 
 
0 / 0  
 
 
111 / 664 
(16.72%) 
 
 
0 / 1 
(0%) 
 
0 / 0  
 
 
0 / 0  
 
 
23 / 145 
(15.86%) 
 
    
0.9090 
a Among 1802 cases, only 1543 subjects were included: 
  2 Subjects were excluded due to missing first diagnosis,14 subjects were excluded due to missing data for subsequent event assessment, and 243 subjects were excluded due to missing data of age, 
gender, stage, and Clark level       
b Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values were based on  the Wald test from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of   
  ancestral allele as the   major  predictor (continuous scale) and  the remaining covariates (age at diagnosis , gender, stage, and Clark level ) were selected by stepwise process using significant level of  
  0.10 to be  entered and kept in the final model. 
c Interaction between two SNPs was  based on  the Wald test  of the interaction term between two SNPs from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of  
  ancestral allele  on two alleles as two   major  predictor (continuous scale) along with the corresponding interaction term  and  the remaining covariates (age at diagnosis , gender, stage, and  
  Clark level ) were selected by stepwise process using significant level of 0.10 to be  entered and kept in the final model. 
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Table 7.2 Interaction of IL-1 SNPs rs1800587 and rs7561 for Composite Outcome 
 
 Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Final Model: by Stepwise Selection process 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
  
 
Ancestral Allele on 
Individual SNP: 
Per 1 copy decrease 
 
 
 
Interaction 
between  
2 SNPs 
Individual   
SNP: 
2 copies 1 copy 0 copies Hazard Ratio 
(95% CI)b 
 P-
valueb 
P- 
valuec 
  IL-1 
  rs1800587 
 
158 / 733 
(21.56%) 
 
126 / 665 (18.95%) 
 
26 / 145 (17.93%) 
 
0.823 
(0.691, 0.979) 
 
0.0283* 
 
  IL-1 
  rs17561 
 
158 / 733 
(21.56%) 
 
126 / 665 (18.95%) 
 
 
26 / 145 
(17.93%) 
 
 
0.821 
(0.690, 0.978) 
 
0.0270* 
 
Combination of 
2 SNPs: 
 
   IL-1  rs1800587  
   and 
 
 
  
2 copies 
 
 
 
1 copy 
 
 
 
0 copies 
   
   
   IL-1 rs7561 
 
 
2  
copies 
 
1 
 copy  
 
0 
copy 
 
2  
copies 
 
1 
copy  
 
0  
copy 
 
2  
copies 
 
1  
copy  
 
0 
 copy 
   
  
158/732 
(21.58%) 
 
0 / 1 
(0%) 
 
 
0 / 0  
 
 
0 / 1  
(0%) 
 
126 / 664 
(18.98%) 
 
 
0 / 0  
 
0 / 0  
 
 
0 / 0  
 
 
26 / 145 
(17.93%) 
 
    
0.9089 
a Among 1802 cases, only 1543 subjects were included: 
  2 Subjects were excluded due to missing first diagnosis, 14 subjects were excluded due to missing data for subsequent event assessment, and 243 subjects were excluded due to missing data of age, 
gender, stage, and Clark level       
b Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values were based on  the Wald test from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of   
  ancestral allele as the   major  predictor (continuous scale) and  the remaining covariates (age at diagnosis , gender, stage, and Clark level ) were selected by stepwise process using significant level of  
  0.10 to be  entered and kept in the final model. 
c Interaction between two SNPs was  based on  the Wald test  of the interaction term between two SNPs from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of  
  ancestral allele  on two alleles as two   major  predictor (continuous scale) along with the corresponding interaction term  and  the remaining covariates (age at diagnosis , gender, stage, and  
  Clark level ) were selected by stepwise process using significant level of 0.10 to be  entered and kept in the final model. 
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Table 7.3 Interaction of TNF-A SNPs rs1800360 and rs361525 for Outcome of Death 
 Endpoint = Death and/or  Recurrent  
Total Event Rate = 310 / 1543 (20.09%) 
Final Model: by Stepwise Selection process 
 
Event Rate: n / N (%) 
Copies of Ancestral  Allele: 
  
 
 
Ancestral Allele on 
Individual SNP: 
Per 1 copy decrease 
 
 
 
 
Interaction 
between  
2 SNPs 
Individual   
SNP: 
2 copies 1 copy 0 copies Hazard Ratio 
(95% CI)b 
 P-
valueb 
P- 
valuec 
   
  TNF-A 
  rs361525 
 
284 / 1367 
 (20.78%) 
 
 
25 / 171  
(14.62%) 
 
 
1 / 5  
(20.00%) 
 
0.707 
(0.481, 1.040) 
 
0.0784 
 
  TNF-A 
  rs1800360 
215 / 1090 
 (19.72%) 
 
86 / 413  
(20.82%) 
 
  9 / 40 
(22.50%) 
 1.206 
(0.976, 1.491) 
0.0825 
 
Combination of 
2 SNPs: 
 
 TNF-A rs361525 
   And 
 
 
  
2 copies 
 
 
 
1 copy 
 
 
 
0 copies 
   
   
   TNF-A 
rs1800360 
 
 
2  
copies 
 
1 
 copy  
 
0  
copy 
 
2  
copies 
 
1 
copy  
 
0  
copy 
 
2  
copies 
 
1  
copy  
 
0 
 copy 
   
  
192/951 
(20.19%) 
 
83 / 376 
(22.07%) 
 
 
9 / 40 
(22.50%)  
 
 
22/134 
(16.42%) 
 
3 / 37 
(8.11%) 
 
 
0 / 0 
 
1 /  5 
(20%)  
 
 
0 / 0  
 
 
0 / 0  
 
    
0.0652 
a Among 1802 cases, only 1543 subjects were included: 
  2 Subjects were excluded due to missing first diagnosis, 14 subjects were excluded due to missing data for subsequent event assessment, and 243 subjects were excluded due to missing data of age, 
gender, stage, and Clark level       
b Hazard ratios, 95% confidence interval (CI) of hazard ratio,  and p-values were based on  the Wald test from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of   
  ancestral allele as the   major  predictor (continuous scale) and  the remaining covariates (age at diagnosis , gender, stage, and Clark level ) were selected by stepwise process using significant level of  
  0.10 to be  entered and kept in the final model. 
c Interaction between two SNPs was  based on  the Wald test  of the interaction term between two SNPs from a Cox proportional hazard model built by stepwise selection process forcing  the copies  of  
  ancestral allele  on two alleles as two   major  predictor (continuous scale) along with the corresponding interaction term  and  the remaining covariates (age at diagnosis , gender, stage, and  
  Clark level ) were selected by stepwise process using significant level of 0.10 to be  entered and kept in the final model. 
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French Validation Results 
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Table 8 French Validation - Dr. Florence Demenaisa 
- Significant Findings 
 
  Study Ednpoint= Death 
  
gene SNP Hazard ratio 
 [95% CI]b 
p- 
value b 
IL-1B rs3136558 0.685 [0.011, 42.803] 0.0719 
IL-6 rs1800797 1.495 [1.116, 2.002] 0.007* 
IL-6 rs1800795 1.501 [1.127, 1.998], 0.005* 
a This validation was performed by the group of Dr. Florence Demenais, Directrice d'Unité : DR1 Inserm, of 
l'Université Paris Diderot - Paris 7, l'Institut Universitaire d'Hematologie. They used independent French data. 
b Hazard ratios and p-values were calculated for per one ancestral allele copy decrease for individual SNPs 
based on a multivariate final model selected via stepwise Cox proportional hazard analysis from a set of 
covariates: age, gender, ethnicity , tumor stage, Clark level, and Breslow index.  
 
 
 
 
Table 9 Pathway Analysis – Genes of the IL1 Pathway Significant for Outcome of 
Recurrence, adjusted for Age of Diagnosis, Gender, Clark Level, Tumor 
Stage, and Breslow Thickness 
 
 
 Endpoint = Recurrence 
Gene P-value 
IL-1 0.035* 
ECSIT 0.02* 
c-JUN 0.008* 
TAK1 0.074* 
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Table 10 Pathway Analysis – All Genes of the IL1 Pathway for Outcomes of Death 
and Recurrence, unadjusted and adjusted for Age of Diagnosis, Gender, 
Clark Level, Tumor Stage, and Breslow Thickness, including number of 
SNPs 
 
 Endpoint = Death 
Unadjusted 
Endpoint = 
Death 
Adjusted 
Endpoint = 
Recurrence 
Unadjusted 
Endpoint = 
Recurrence 
Adjusted 
Number 
of SNPs 
included 
for each 
Gene 
Gene P-value P-value P-value P-value  
IL-1 0.315 0.122 0.115 0.035* 539 
IL-6 0.122 0.507 0.176 0.467 719 
IL-8 0.202 0.386 0.338 0.522 377 
IFN-G 0.619 0.972 0.425 0.893 657 
TNF-A 0.785 0.608 0.933 0.824 499 
c-JUN 0.35 0.18 0.279 0.008* 193 
ECSIT 0.632 0.188 0.158 0.02* 193 
IkBa 0.448 0.263 0.76 0.536 193 
IKKa 0.448 0.263 0.76 0.536 193 
IKKb 0.042 0.475 0.072 0.611 193 
IL1R1 0.962 0.889 0.35 0.803 193 
IL1RA 0.63 0.848 0.68 0.784 193 
IL1RAcP 0.854 0.644 0.947 0.737 193 
IRAK4 0.533 0.357 0.385 0.145 193 
JNK 0.337 0.918 0.231 0.955 193 
MEK3 0.396 0.73 0.639 0.865 193 
MEK6 0.617 0.47 0.727 0.579 193 
MEKK1 0.693 0.862 0.719 0.889 193 
MYD88 0.906 0.424 0.701 0.584 193 
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 Endpoint = Death 
Unadjusted 
Endpoint = 
Death 
Adjusted 
Endpoint = 
Recurrence 
Unadjusted 
Endpoint = 
Recurrence 
Number 
of SNPs 
included 
for each 
Gene 
Gene P-value P-value P-value P-value  
NF-kB 0.246 0.548 0.272 0.489 193 
NIK 0.644 0.687 0.639 0.218 193 
P38 0.643 0.621 0.803 0.909 193 
RKIP 0.753 0.87 0.968 0.973 193 
TAB1 0.367 0.633 0.263 0.526 193 
TAK1 0.281 0.123 0.459 0.074* 193 
TOLLIP 0.404 0.635 0.534 0.7 193 
TRAF6 0.187 0.553 0.275 0.632 193 
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Figure 3. Q-Q Plot of Adjusted Probabilities of Genes for Death Outcome 
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Figure 4. Q-Q Plot of Adjusted Probabilities of Genes for Recurrence Outcome 
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Table 11a.    Baseline Demographics, Clinical Characteristics, and RNA Expression 
        Level by Subjects with or without Endpoint of Death  
        among All Melanoma Cases in TCGA  dataset (Total N = 194a) 
 
  
Endpoint = Death 
Event Rate = 85 / 194 (43.8%) 
  
All  
Melanoma  
Cases 
Baseline Demographics & 
Clinical Characteristics 
Event 
 (N =85 ) 
No Event 
 (N =109 ) 
  
 ( N =194 ) 
Gender: n (%) 
   - Male 
   - Female 
 
 
54 (63.5%) 
31 (36.5%) 
 
66 (60.5%) 
43 (39.5%) 
  
120 (61.9%) 
74 (38.1%) 
Age at First Diagnosis (Years): 
    Mean ± SD 
 
 
58.7  ± 15.9 
 
 
55.1 ± 16.2 
 
  
56.7 ± 16.2 
Stage: n(%) 
   - I & I/II 
   - III & IV 
    
 
27 (31.8%) 
58 (68.2%) 
 
 
31 (28.4%) 
78 (71.6%) 
 
  
58 (29.9%) 
136 (70.1%) 
 
Clark Level: n(%) 
   - 1, 2, 3 
   - 4 & 5 
    
 
26 (30.6%) 
59 (69.4%) 
 
 
52 (47.7%) 
57 (52.3%) 
 
  
78 (40.2%) 
116 (59.8%) 
 
Breslow Index: 
    Mean ± SD 
     
 
4.77 ± 6.89 
 
 
4.87 ± 8.78 
 
  
4.82 ± 7.99 
 
RNA Expression Level     
IL-1 RNA Level 
  - Continuous (units): Mean ± SD 
   - Binary: n (%) 
   <= 35 units 
   - > 35 units     
 
85.0 ± 178.4 
 
46 (54.1%) 
39 (45.9%) 
 
124.3 ± 354.0 
 
51 (46.8%) 
58 (53.2%) 
  
107.1 ± 290.5 
 
97 (50.0%) 
97 (50.0%) 
ECSIT RNA Level 
  - Continuous (units): Mean ± SD 
   - Binary: n (%) 
   <= 670 units 
   - > 670 units 
     
 
758.8 ± 350.6 
 
41 (48.2%) 
44 (51.8%) 
 
724.5 ± 408.6 
 
56 (51.4%) 
53 (48.6%) 
 
  
739.5 ± 383.7 
 
97 (50.0%) 
97 (50.0%) 
 
c-JUN RNA Level 
  - Continuous (units): Mean ± SD 
   - Binary: n (%) 
   <= 1470 units 
   - > 1470 units 
     
 
2134.5 ± 2180 
 
44 (51.8%) 
41 (48.2%) 
 
2001.4 ± 1554 
 
54 (49.5%) 
55 (50.5%) 
 
  
2059.7 ± 1850.4 
 
98 (50.5%) 
96 (49.5%) 
 
a TCGA dataset was downloaded from the website: https://tcga-  
  data.nci.nih.gov/tcga/tcgaHome2.jsp. Among 305 melanoma cases, only 194  
 subjects with complete data were included.
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Table 11b  Relationship between RNA Expression Level (as Continuous Variable) and the Melanoma Endpoint of Death  
        from TCGA Dataset (Total N = 194a)  via Unadjusted and Adjusted Logistic Regression Analysis 
 
 IL-1 RNA Level  ECSIT RNA Level  c-JUN RNA Level 
Parameter Odds Ratio (95% CI)b 
p-value  Odds Ratio 
(95% CI) 
p-value  Odds Ratio 
(95% CI) 
p-value 
RNA Level ( Continuous):   
 Summary Statistics: Mean ±SD 
- Deaths (N = 85) 
       - Survivors (N =109)  
 
 
    
    85.0 ± 178.4 
124.3 ± 354.0 
 
 
 
 
 
 
 
 
    
758.8 ± 350.6 
72453 ±408.6 
 
 
 
 
 
 
 
 
 
2134.5 ± 2180 
2001.4 ± 1554 
 
 Odds ratio for per one unit increase: 
o Unadjusted 
 
 
0.999                   
(0.998, 1.001) 
 
0.3704 
  
1.000                   
(0.999, 1.001) 
 
0.5364 
  
1.000                   
(1.000, 1.000) 
 
0.6200 
 
      
  
o Adjusted 1.000          (0.998, 1.001) 
0.5409  1.000           
(0.999, 1.001) 
0.6391  1.000                   
(1.000, 1.000) 
0.8167 
        Covariates: 
            - Age at first diagnosis: per  one year increase 
1.015         
(0.996, 1.034) 0.1345 
 1.015           
(0.996, 1.034) 0.1210 
 1.015           
(0.996, 1.034) 0.1262 
- Gender: Male vs. Female 1.215           (0.661, 2.232) 0.5306 
 1.211           
(0.650, 2.228) 0.5377 
 1.200           
(0.653, 2.202) 0.5572 
- Tumor Stage:  III & IV vs. I & I/II 0.546           (0.264, 1.127) 0.1019 
 0.553           
(0.268, 1.142) 0.1092 
 0.551           
(0.267, 1.137) 0.1068 
- Clark Level: 4 & 5 vs. 1, 2, & 3 2.513       (1.287, 4.907) 00070* 
 2.545           
(1.304, 4.966) 00062* 
 2.556               
(1.311, 4.984) 00059* 
- Breslow Index: Per one unit increase 0.993          (0.956, 1.032) 0.7342 
 0.991           
(0.954, 1.030) 
0.6539  0.993           
(0.956, 1.032) 0.7328 
a TCGA dataset was downloaded from the website: https://tcga-    data.nci.nih.gov/tcga/tcgaHome2.jsp.  
  Among 305 melanoma cases, only 194 subjects with complete data were included. 
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Table 11c.   Relationship between RNA Expression Level (as Binary Variable: > vs. <= Median ) and the Melanoma  
                  Endpoint of Death from TCGA Dataset (N = 194a)  via Unadjusted and Adjusted Logistic Regression Analysis 
 
 
IL-1 RNA Level: 
>  vs. <= Median: 35 units 
 ECSIT RNA Level: 
>  vs. <= Median: 670units 
 c-JUN RNA Level: 
>  vs. <= Median: 1470 units 
Parameter Odds Ratio (95% CI)b 
p-value  Odds Ratio 
(95% CI) 
p-value  Odds Ratio 
(95% CI) 
p-value 
RNA Level ( Continuous):   
 Summary Statistics:   n / N (%) of > Median 
- Deaths (N = 85) 
       - Survivors (N =109)  
 
    
    
39 / 85 (45.9%)  
58 / 109 (53.2%) 
 
 
 
 
 
  
    
    
44 / 85 (51.8%)  
53 / 109 (48.6%) 
 
 
 
 
 
  
    
    
41 / 85 (48.2%)  
55 / 109 (50.5%) 
 
 Odds ratio for per one unit increase: 
o Unadjusted 
 
 
0.746                   
(0.422, 1.317) 
 
0.3116 
  
1.134                   
(0.643, 2.000) 
 
0.6643 
  
0.915 
 (0.519, 1.614) 
 
0.7587 
 
      
  
o Adjusted 
 
0.782                   
(0.428, 1.430) 
 
0.4250 
  
1.083                   
(0.601, 1.952) 
 
0.6643 
  
0.892 
 (0.495, 1.607) 
 
0.7038 
        Covariates: 
            - Age at first diagnosis: per  one year increase 
1.013            
(0.994, 1.033) 0.1773 
 1.015               
(0.996, 1.035) 0.1162 
 1.015           
(0.996, 1.035) 0.1150 
- Gender: Male vs. Female 1.223            (0.664, 2.252) 0.5178 
 1.199            
(0.654, 2.201) 0.5573 
 1.196           
(0.652, 2.104) 0.5630 
- Tumor Stage:  III & IV vs. I & I/II 0.544            (0.263, 1.123) 0.0999 
 0.553           
(0.267, 1.144) 0.1104 
 0.544           
(0.264, 1.122) 0.0993 
- Clark Level: 4 & 5 vs. 1, 2, & 3 2.581                  (1.323, 5.036) 00054* 
 2.547                  
(1.305, 4.970) 00061* 
 2.555           
(1.311, 4.981) 00059* 
- Breslow Index: Per one unit increase 0.992                    (0.955, 1.031) 0.6958 
 0.993           
(0.956, 1.031) 
0.7090  0.992           
(0.955, 1.031) 0.6907 
a TCGA dataset was downloaded from the website: https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp. Among 305 melanoma cases, only 194 subjects with 
complete data were included. 
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Table 12a.    Baseline Demographics, Clinical Characteristics, and Protein  
Expression Level by Subjects with or without Endpoint of Death  
among All  Melanoma Cases in TCGA   dataset (Total N = 119a) 
 
  
Endpoint = Death 
Event Rate = 55 / 119 (46.2%) 
 All  
Melanoma  
Cases 
 
 
Baseline Demographics & 
Clinical Characteristics 
 
Event 
 (N =55 ) 
 
No Event 
 (N =64 ) 
  
 ( N =119 ) 
Gender: n (%) 
   - Male 
   - Female 
 
 
34 (61.8%) 
21 (38.2%) 
 
40 (62.5%) 
24 (37.5%) 
  
74 (62.2%) 
45 (37.8%) 
Age at First Diagnosis (Years): 
    Mean ± SD 
 
 
60.9  ± 15.1 
 
 
53.4 ± 15.9 
 
  
56.9 ± 15.9 
Stage: n(%) 
   - I & I/II 
   - III & IV 
    
 
18 (32.7%) 
37 (67.3%) 
 
 
22 (34.4%) 
42 (65.6%) 
 
  
40 (33.6%) 
79 (66.4%) 
 
Clark Level: n(%) 
   - 1, 2, 3 
   - 4 & 5 
    
 
17 (30.9%) 
38 (69.1%) 
 
 
29 (45.3%) 
35 (54.7%) 
 
  
46 (38.7%) 
73 (61.3%) 
 
BreslowIndex:  
    Mean ± SD 
     
 
4.80 ± 7.19 
 
 
3.70 ± 5.19 
 
  
4.21 ± 6.20 
 
Protein Expression Level     
c-JUN Protein Level 
  - Continuous (units): Mean ± SD 
 
   - Binary: n (%) 
     <= -1.12 units 
      > -1.12 units 
  
 
-1.211 ± 0.424 
 
 
41 (74.5%) 
14 (25.5%) 
 
 
-0.918 ± 0.689 
 
 
35 (54.7%) 
29 (45.3%) 
  
-1.053± 0.598 
 
 
76 (63.9%) 
43 (36.1%) 
 
a TCGA dataset was downloaded from the website: https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp. 
Among 206 cases, only 119 subjects with complete data were included. 
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Table 12b.  Relationship between c-JUN Protein Expression Level (as Continuous  
                  Variable) and the Melanoma Endpoint of Death from TCGA Dataset  
                   (Total N = 119a) via Unadjusted and Adjusted Logistic Regression  
                    Analysis 
 
 c-JUN Protein Expression Level 
Parameter Odds Ratio   (95% CI) 
p-value 
c-JUN Protein Level ( Continuous):   
 Summary Statistics: Mean ±SD 
- Deaths (N = 55) 
       - Survivors (N =64)  
 
 
 
-1.211 ± 0.424 
-0.918 ± 0.689 
 
 
 Odds ratio for per one unit increase: 
o Unadjusted 
 
 
0.405 (0.204, 0.804) 
 
0.0098* 
 
  
o Adjusted 0.407 (0.196, 0.844) 0.0156* 
        Covariates: 
            - Age at first diagnosis: per  one year increase 
1.031(1.005, 1.058) 0.0213* 
- Gender: Male vs. Female 0.882 (0.390, 1.994) 0.7631 
- Tumor Stage:  III & IV vs. I & I/II 0.706 (0.257, 1.937) 0.4992 
- Clark Level: 4 & 5 vs. 1, 2, & 3 2.140 (0.848, 5.406) 01074 
- Breslow Index: Per one unit increase 1.017 (0.952,  1.086) 0.6262 
a TCGA dataset was downloaded from the website:  https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp. 
   Among 206 cases, only 119 subjects with complete data were included. 
. 
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Table 12c.  Relationship between c-JUN Protein Expression Level (as Binary   
       Variable: > vs. <= Median of -1.12 units) and the Melanoma Endpoint of  
       Death from  TCGA Dataset (Total N = 119a)  via Unadjusted and    
      Adjusted Logistic Regression Analysis 
 
 c-JUN Proein Expression Level 
Parameter Odds Ratio   (95% CI) 
p-value 
c-JUN Protein Level ( Binary): 
 Summary Statistics:   n / N (%) of > Median 
- Deaths (N = 55) 
       - Survivors (N =64)   
 
 
 
14 / 55 (25.5%) 
29 / 64 (45.3%) 
 
 
 Odds ratio for > vs. <=  median of -1.12 units: 
o Unadjusted 
 
 
0.412 (0.189, 0.900) 
 
0.0262* 
 
  
o Adjusted 0.417 (0.182, 0.0.957) 0.0390* 
        Covariates: 
            - Age at first diagnosis: per  one year increase 
1.031(1.005, 1.058) 0.0211* 
- Gender: Male vs. Female 0.823 (0.367, 1.843) 0.6354 
- Tumor Stage:  III & IV vs. I & I/II 0.631 (0.234, 1.702) 0.3634 
- Clark Level: 4 & 5 vs. 1, 2, & 3 2.238 (0.891, 5.622) 0.0864 
- Breslow Index: Per one unit increase 1.021 (0.954,  1.093) 0.5444 
a TCGA dataset was downloaded from the website:  https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp. 
   Among 206 cases, only 119 subjects with complete data were included. 
. 
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Chapter 4 
Discussion 
All the specific SNPs for the upstream and downstream genes in the IL-1 pathway 
were specifically selected because they had been selected before in previous studies for 
showing prior indication of association with human disease, including cancer and its genesis.  
These studies would include Lee, K.M. et al. (2007), Van Dyke, A.L. et al. (2009), Erdei, E 
et al. (2010), and Karakus, N. et al. (2011). Regarding the discrepancy in the results for the 
individual SNP analysis between this study and the French validation, the most likely 
explanation would be differences in genetic composition between the subjects from the States 
and those from France, along with certain differences in lifestyle and environmental factors 
such as exposure to the sun. It is interesting to note that for the composite outcome, r1800587 
and rs17561 had hazard ratios with significant p-values and were less than 1, along with the 
95% CI. There seems to be an indication that the non-ancestral alleles for these two SNPs 
might have a protective effect for melanoma outcome and would merit future investigation. 
Ultimately, more fruitful results were found from the pathway analysis. The results of the 
individual SNP analysis proved to be intriguing, if inconclusive. One drawback that should 
be noted is that using the composite outcome of death and/or recurrence would be deemed 
slightly odd, and that melanoma-specific survival would be more typical. 
 Regarding the potential protective role c-JUN may play in melanoma outcome, 
Kappelmann et al. (2013) reported that the production of c-JUN protein is regulated at the 
post-transcription level. There are microRNAs directing the regulation of c-JUN protein 
expression. This report could explain the lack of significance for c-JUN at the RNA level. 
Kunz (2013) observed that melanoma-associated microRNAs are frequently located in 
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genomic regions, often showing gains and losses in tumors. However, using logistic 
regression, c-JUN was found to be significant at the protein level for both unadjusted and 
adjusted for the key covariates, whether c-JUN was treated as categorical or continuous, with 
p-values well under 0.05. The same phenomenon might hold true for IL-1 showing 
significance at the protein level, despite the lack of significance at the RNA level. Due to the 
lack and limitation of available human data, it will have to wait for a future study. 
 The pathway analysis showed borderline significance for the TAK1 gene, but there 
was no RNA or protein expression data available, but for a future study, it would be useful to 
consider the reason for these results. Regarding why such results were seen, transforming 
growth factor-β activated kinase-1 (TAK1) is crucial for the cellular response cascade caused 
by changes in the environment. It is controlled by cytokines including specifically 
interleukin-1 (IL-1) and transforming growth factor-β (TGF-β). TAK1 is also critical for in 
turn activating key intra-cellular kinases, such p38 MAPK and c-jun N-terminal kinase 
(JNK). Landström (2010) has indicated that TAK1 is implicated in the activation of tumor 
suppressor protein, LKB1 kinase. The LKB1 kinase in turn can go on to activate 14 kinases. 
What is important to note about TAK1 is that it is acting upstream in all these pathways, 
further highlighting its key function of TAK1 in modulating the cellular response to cytokines 
and stress.  
 As was mentioned in the introduction, this study did not simply use individual SNP or 
candidate gene analysis; it implemented a full pathway analysis of all the genes in the IL-1 
pathway, incorporating all available SNPs. The reasons for such are that previous candidate 
gene studies reported variants in genes related to immunosuppressive mechanisms. The 
studies focused on some sets of SNPs, but the sample sizes were relatively small, and the 
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results were at times inconsistent. Analysis of the SNPs of individual genes from this GWAS 
will thus serve to further elucidate and build upon the results from the previous studies. After 
the analysis of the individual SNPs, it is intended that a pathway analysis be performed.  
 Such previous studies can be underpowered in detecting weak associations with 
susceptibility to disease at the genome-wide significance level. The idea for a pathway 
analysis is that SNPs in a group of genes with a common biological function might show 
significant association at the overall pathway level, even if no individual SNP shows 
association at a proper level of statistical significance. From there, if any genes are found to 
be significant, statistical analysis of RNA and protein expression levels for those genes will 
proceed as the final stage of verification, hopefully finding a novel target for therapy. 
 IL-10, IL-6, and IFN-γ (Martínez-Escribano, 2002) all have reports involving tumor 
growth or shrinkage. In this study, these cytokines did not show significant correlation with 
the melanoma outcomes of death and recurrence (data not shown). The bioinformatical 
analysis suggests that these cytokines may not be major impact factors for melanoma. 
To go further into c-JUN, it combines with c-FOS to form the AP-1 transcription 
factor. AP-1 is responsible for regulating the expression of genes depending on stimuli, 
which include cytokines and other things like growth factors and bacterial or viral infections. 
AP-1 is also responsible for overseeing, among other things, apoptosis and proliferation. c-
JUN is activated via double phosphorylation of the JNK pathway. It is interesting to note that 
knocking out c-JUN causes lethality, but transgenic animal models with a mutated c-JUN 
form that is unable to be phosphorylated are actually viable.  
Some other interesting details about c-JUN are that it is the transforming gene of 
avian sarcoma virus 17. c-JUN is a gene without introns, located on 1p31-1p32. That 
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chromosomal region happens to be distinct for its role regarding translocations and deletions 
influencing diseases. c-JUN is positively self-regulated by its own product, which binds to 
the promoter region to further induce transcription. As for c-JUN’s links to other pathways, 
c-JUN activity can be affected by the ERK pathway. ERK increases transcription of c-JUN.  
c-JUN is crucial and necessary for the flow of the cell cycle, specifically the G1 
phase. Without c-JUN, cells show arrest of the G1 phase. Specifically, c-JUN is required for 
cyclin D1 kinase function, which allows the cell cycle to continue flowing.  
c-JUN is known for anti-apoptotic activity. Specifically, it can be activated by UV 
irradiation. c-JUN shields cells from apoptosis induced by UV irradiation. It can also work 
with NF-κβ to prevent apoptosis triggered by TNF-α.   
c-JUN is mainly considered an oncogenic factor in malignant melanoma and many 
other cancer types (Kappelman et al., 2013). It is surprising to observe that c-JUN shows a 
protective role in melanoma mortality and recurrence. The reason for this discrepancy is not 
clear. Yamanishi et al. (1991) reported metastatic melanoma cells expressing low c-JUN 
RNA transcript activity. The results of this study correspond with those of Yamanishi et al. 
(1991). It is possible that the discrepancy could be similar to the observations that IL-1 shows 
either pro- or anti-tumor functions depending upon the circumstances. It awaits further 
clarification. 
As to how this discovery might help explain lack of results for drug treatments for 
melanoma, one example would be B-RAF inhibitors such as vemurafenib. B-RAF with the 
V600 mutation activates the MAPK pathway, affecting MEKK1, which is part of the IL-1 
pathway. However, while MEKK1 leads down to the activation of c-JUN, it is responsible for 
the other branch of the IL-1 pathway leading down to the other component of NF-κβ. NF-κβ 
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could be connected to other pathways that help it maintain activation despite the disruption of 
MEKK1. That could help explain tumor mechanisms for adapting against the BRAF 
inhibitors. Furthermore, as previously noted, c-JUN is positively self-regulating, so once 
there is already some protein product, c-JUN can presumably continue maintaining activation 
and production even with the upper part of the pathway flowing from MEKK1 being 
inhibited.  
 As far as is known, this study is the first full pathway design correlating c-JUN 
activity with melanoma outcome. The pathway/mechanism for this protective/anti-
proliferation effect is unclear. However, using breast cancer as a model, Xu et al. (2013) 
showed that inhibition of the Tamoxifen-stimulated cells was positively regulated by 
overexpression of c-JUN and vice versa for underexpression of c-JUN. The exact mechanism 
for the anti-proliferation is unknown, though it does occur through the protein kinase C 
(PKC) pathway. It could be the same for melanoma or perhaps a similar pathway. Based on 
this bioinformatics analysis, the results suggest that therapeutically targeting c-JUN activity 
may be an effective way to enhance the rate of curing malignant melanoma. 
 In conclusion, the bioinformatical analyses did not show significant correlation of 
studied IL-1, Il-6, IL-8, IFN-γ, and TNF-α SNPs with melanoma mortality, recurrence or 
composite outcome of both. Full pathway analysis of all SNPs from every gene in the IL-1 
pathway showed that c-JUN protein expression is significantly negatively correlated with 
mortality and recurrence. The expression and function of c-JUN may serve as a therapeutic 
target for metastatic melanoma. 
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